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ABSTRACT

Associations of Chronic Infectious and Non-infectious Disease Comorbidities with HIV Clinical
Outcomes
By
NANG THU THU KYAW

July 22, 2020

Globally, nearly 3% of the 38 million people living with HIV (PLHIV) died in 2018.
Underlying comorbidities in PLHIV present critical challenges to clinical care and contribute to
increased mortality in PLHIV. Key infectious disease comorbidities include tuberculosis (TB),
hepatitis B virus (HBV), and hepatitis C virus (HCV). Given the rapid expansion of type 2 diabetes
mellitus (T2DM) worldwide, T2DM is an emerging non-infectious disease comorbidity among
PLHIV. All four of these comorbidities are associated with increased mortality in PLHIV.
Currently there is an urgent need to develop clinical guidelines for HIV programs that integrate
prevention, screening, and treatment for comorbidities. However, existing data that quantifies the
impact of comorbidities on HIV outcomes are limited, especially in resources limited settings. To
answer critical questions related to the effects of comorbidities on health outcomes in PLHIV, we
conducted three observation studies using the clinical data of PLHIV from Myanmar.
In study 1, we assessed biological interaction between hyperglycemia and low body mass
index (BMI) on the risk of TB disease among patients entering HIV care. Cox proportional hazard
models were used to estimate the rates of TB disease due to hyperglycemia, due to low BMI, and
due to joint exposure (hyperglycemia and low BMI). We used continuous, categorical, and spline
measures of hyperglycemia and low BMI to model the dose-response relationship with TB
incidence. We performed sensitivity analyses to assess the direction and magnitude of bias in
estimation of the association between low BMI and hyperglycemia with TB incidence due to
unmeasured confounders, exposure misclassification, and competing risks. We reported a
biological interaction between BMI and hyperglycemia on the risk of TB disease [relative excess
risk of TB disease due to joint exposure: 0.42, 95% CI:0.07, 0.78].
Study 2 focused on the relationship between TB disease and key clinical outcomes in
PLHIV, including all-cause mortality, CD4+T cell response, and virological failure. Study 2 also
assessed the role of glycemic status as a mediator in the relationship between active TB and all-

cause mortality. This study used log binomial regression, general linear mixed models, and
mediation analysis to achieve the analysis objectives. After one-year of follow-up time, we
observed an association between active TB with all-cause mortality [adjusted hazard ratio (aHR):
1.75, 95% CI: 1.38, 2.21]. The mean log CD4 cell count during the follow-up was significantly
lower in PLHIV with active TB compared to those without active TB [βTB = -0.61, 95% CI: -0.71,
-0.51, βTB*follow-up month= 0.04, 95% CI: 0.03, 0.05]. However, we did not observe glycemic level to
be a key mediator in the relationship between TB disease and all-cause mortality.
Study 3 examined whether associations between HBV/HCV coinfection and all-cause
mortality differed by hyperglycemia status among PLHIV. We used Cox proportional hazards
models to compare all-cause mortality rates in participants by HCV/HBV coinfection and
hyperglycemia status. We reported coinfections with hepatitis increased rates of all-cause
mortality [aHR: 1.25, 95% CI: 1.11, 1.40] for HBV, 1.52, 95% CI: 1.35, 1.71] for HCV, and 2.14,
95% CI: 1.51, 3.02] for HBV/HCV coinfection compared to HIV mono-infection]. The observed
associations were greater in HCV and HBV/HCV coinfected patients with hyperglycemia [aHR:
1.85, 95% CI: 1.23, 2.78 for HCV and 4.39, 95% CI 1.51, 12.76 for HBV/HCV coinfection].
Findings from this dissertation will inform clinical care of PLHIV in low- and middleincome countries. Our results suggest that 1) PLHIV with hyperglycemia and low BMI represent
a subgroup with high risk of TB incidence, 2) PLHIV with active TB experience higher mortality
and lower mean CD4 cell counts during the follow-up, and 3) hepatitis coinfection and
hyperglycemia are associated with higher risk of mortality in PLHIV. We highlight in this
dissertation the need for guidelines to prevent and manage TB, HBV, HCV and hyperglycemia in
PLHIV.
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Chapter 1: Literature Review and Statement of Purpose
1.1 Global burden of HIV, TB, HBV/HCV and diabetes mellitus
Globally, human immune deficiency virus (HIV), tuberculosis (TB) and hepatitis B virus
(HBV), hepatitis C virus (HCV) infections and type 2 diabetes mellitus (T2DM) are still significant
global health burdens. Although the incidence of HIV has been declining globally over the last
decade, the rate of decline is slow to meet the United Nation Sustainable Development Goal’s
(SDG) target to end the HIV epidemic by 2030 (<200,000 new HIV infection per year) [1,2].
Worldwide in 2018, an estimated 37.9 million people were living with HIV (PLHIV), and 1.7
million people were newly infected with HIV [3]. During the last decade, the trend of HIV-related
deaths has decreased globally with the increasing access to antiretroviral therapy (ART). However,
nearly a million people still died from HIV-related illnesses globally in 2017 and HIV was ranked
as 8th in the leading cause of death. Moreover, declined in the incidence of HIV and HIV-related
mortality is not homogeneous across countries or population. The incidence of HIV has declined
slower in developing countries where HIV infections are concentrated among the key population
[2]. In addition, most of the HIV-related deaths are in HIV-infected patients with comorbidities
such as TB disease and other non-AIDS-related conditions [4].
Similarly, the incidence of TB disease has declined globally. However, the rate of decline
still needs to accelerate to reach the End TB target of the SDG by 2030 (<10 incident TB cases per
100,000 population per year) [5]. There were 10 million incident TB cases in 2017 with 1.6 million
people died from TB which is one of the top 10 causes of death worldwide. The burden of TB is
not distributed equally across the world as more than 95% of the case and deaths were from
developing countries and half of them were in South-east Asia and Western Pacific Region [6].
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People living with HIV, those with T2DM, tobacco users and children have higher risk of TB and
TB related deaths.
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are another infectious disease of
global concern due to their high public health burden. In 2015, estimated 240 million people had
chronic HBV infection and 150 million had chronic HCV infection [7]. It is estimated that more
than 686,000 people die each year from HBV infection and 700,000 from HCV infection.
While the global disease burden due to infectious diseases such as HIV and TB has
declined, the disability and early mortality due to non-t diseases have increased by 40% between
1990 and 2017 [8]. One of the SDG’s target is to reduce the premature mortality due to noninfectious disease by one third by 2030 [1]. T2DM is one of the primary non-infectious chronic
disease and one of the leading cause of death in the world [9]. In 2016, 422 million people living
with DM, of which more than 90% of them were T2DM and 1.6 million died from DM, of which
85% of them were from low- and middle-income countries.
In many low- and middle-income countries, the control of infectious disease have not yet
achieved while the disease epidemic has been shifted from infectious disease to chronic noninfectious disease [10,11]. Global data shows that the prevalence of T2DM is increasing in the
countries which bear the brunt of the HIV and TB epidemic [6,12,13]. Converging of infectious
and non-infectious diseases in the low- and middle-income countries threatens the global progress
of the control of these diseases. Hence, it is critical to understand the association and interaction
between each of these diseases to optimize the screening and management of TB, HIV, HBV/HCV
and T2DM to reduce disease-related morbidity and mortality.
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1.2 Tuberculosis comorbidity and HIV clinical outcomes
Tuberculosis (TB) is the principal comorbidity and the leading cause of death among
people living with HIV (PLHIV) [6,14–16]. Nine per cent (920,000 cases) of the incident TB cases
occurred in PLHIV in 2017. Nearly one-third of a million HIV-related global deaths in 2018 were
attributed to TB disease [13].
TB is the disease caused by bacteria called Mycobacterium tuberculosis (Mtb), an airborne
infection transmitted through inhalation of droplets containing Mtb. TB is primarily a pulmonary
disease but can also cause disease in extrapulmonary organs and systems. Once infected with Mtb,
most of the host eliminate or contain the infection without symptom while some of the progress to
active TB disease depending on the host innate and adaptive immune response and bacteria
virulence. The former state is classified as a latent TB infection. One-third of the global population
estimated to have latent TB infection which can progress or reactive to an active TB disease. Active
pulmonary disease is presented by symptoms such as cough with productive sputum, fever, weight
loss which can be contagious. Some of the infected people develop an active extrapulmonary TB
disease in which the symptoms will depend on the sites of the disease [17,18]. Individual can
advance or reverse the stages in the spectrum of TB (infection eliminated, latent TB infection, subclinical TB disease, active TB disease and reactivation of TB disease) depending on the host
immune response and comorbidities.
In non-HIV population, the risk of reactivation from latent TB infection to active TB
disease is 10% in their lifetime. However, in HIV-positive patients, the course of Mtb infection is
altered and the lifetime risk of development or recurrence of active TB disease increase to 2 to 5
times during the early and chronic phase of infection and 20 to 37 times during the severe
3

immunodeficiency stage compared to the non-HIV population [19]. The incidence rate of TB
disease in HIV-positive patients reported from different epidemiology studies was range from 1.9
to 9.5 TB cases per 100 person-years follow-up among those who were not on ART treatment and
from 0.5 to 4.4 per 100 person-years follow-up among those on ART [20–22]. The risk of TB
disease in HIV increases while the immune level decrease (clinically measured by CD4+T cell
count and WHO HIV clinical staging) [23,24], and the ART is the most effective way to reduce
the risk of TB disease in HIV patients by restoring the immune function [25]. However, the risk
of TB disease in PLHIV on ART with normal immune level is still higher than the risk of TB
disease in the non-HIV population [21].
In addition, comorbidity with TB in HIV patients increases the risk of mortality by fourfold [26]. The host-pathogen interactions involved in HIV and TB coinfection leads to unfavorable
clinical outcomes in HIV/TB co-infected patients [19,27]. First, co-infection with TB promotes
the rapid HIV disease progression as a result of the increase in HIV replication and propagation
due to increased immune activation during the host response to TB [28–30]. Second, HIV attacked
the CD4 cell and macrophages which are important for host defense against Mtb. HIV depletes
CD4 cell which produces interferon-γ which is important for autophagic clearance of Mtb [31].
HIV can also infect the macrophage and inhibit the killing (phagocytosis and autophagy) of Mtb
in the macrophages. Third, both HIV and TB diseases are considered as chronic inflammatory
diseases. DNA products from HIV activate inflammasome and effector molecules from TB
bacteria release pro-inflammatory cytokines resulting in cavitation and releasing of bacteria into
extracellular spaces causing severe TB disease. Finally, due to the downregulation of innate
immune and immunoregulatory response to TB by HIV before ART, the exaggerated
inflammatory response, known as tuberculosis-associated immune reconstitution inflammatory
4

syndrome, occurs once the patient is initiated on ART which worsens the TB disease leading to
early ART mortality [32].
Hence, TB comorbidity poses substantial challenges for HIV clinical management.
HIV/TB patients experience poor clinical outcomes such as impaired in immune recovery and
higher mortality [33,34]. Subclinical presentation of TB disease in HIV is also common, resulting
in delayed in TB diagnosed, contributing to the increased mortality in HIV/TB patients. Signs and
symptoms of TB in HIV patients are different and severe than non-HIV population [35] and the
traditional diagnosis tools such as tuberculin skin test for TB infection or sputum smear
microscopy for TB disease are not sensitive in HIV/TB patients leading to challenges in the
management of both diseases. Although ART can reduce the risk of TB-related mortality in
HIV/TB patients, several factors and mechanisms listed above contribute to increased risk of
mortality among HIV/TB coinfected patients even on ART compared to infection with HIV or TB
alone [28,30,33,36,37]. Most of the HIV patients (5-40%) had active TB at the first time of
presenting to health facilities missing the opportunities to receive TB preventive therapy (latent
TB treatment to prevent progression to or reactivation of TB disease) or ART to reduce the risk of
TB disease. Hence, optimal management of HIV/TB co-infected patients is critical to lowering
HIV-related mortality globally.
1.4 Hepatitis B and C virus coinfection and HIV clinical outcomes
As HIV and HBV or HCV share a common route of transmission, HIV and HBV or HCV
coinfection is not uncommon. Globally, 3 to 6 million people with HIV were estimated to be coinfected with HBV and about 2.3 million people living with HIV were estimated to be co-infected
with HCV in 2015 [38,39]. Studies have suggested that HIV co-infection with hepatitis B and/or
5

C infections increases the risk of chronic infection and liver disease, accelerates liver fibrosis and
complicates the management of both infections leading to increased mortality [40–43]. However,
there are some studies suggested that hepatitis C coinfection did not increase the mortality in the
studies conducted before the era of highly active ART but did increase the mortality in studies
included patients on ART [44]. Previous studies showed that the successful treatment of HBV and
HCV together with ART can limit the liver damage and reduce mortality [45–47]. However, access
to HBV and HCV treatment is very limited in low and middle-income countries and the mortality
related to HBV and HCV in PLHIV could be still high.
1.3 Type 2 diabetes mellitus comorbidity and HIV clinical outcomes
T2DM is one of the types of DM characterized by the underlying pathophysiology of
insulin resistance in muscle, fat and liver, insulin deficiency due to impaired insulin secretion,
excessive hepatic glucose production and abnormal fat metabolism. Insulin is required for muscle
and liver cells to use glucose to regulate blood glucose level. Increased adipocyte (fat cell)
increases the secretion of adipokines which in turn impaired utilization of insulin by muscle and
liver cell leading to hyperglycemic state. Also, products of adipocytes and adipokines increase the
release of pro-inflammatory cytokines resulting in an inflammatory state that can enhance insulin
resistance in adipocyte, liver and muscle. Chronic state of hyperglycemia due to T2DM can result
in micro and macrovascular complications such as cardiovascular disease, blindness, end-stage
renal disease, amputations, and hospitalizations. T2DM can be diagnosed by measuring blood
glucose level using fasting blood glucose (FBG), oral glucose tolerance test (OGTT) or glycated
haemoglobin (HbA1c) and managed the glycemic level by oral hypoglycemic drugs or injection
insulin to prevent complications.
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Although there are mixed results regarding higher prevalence and incidence of T2DM and
hyperglycemia among HIV compared to the general population, many of the studies pointed to
increase risk of T2DM among HIV patients compared to the general population [48–51]. The
incidence of T2DM in HIV-positive Canadian men was reported to be 1.39 times higher than men
in the general population of similar age [50]. Similarly, in the studies from Brazil and Italy, the
T2DM prevalence trend was increasing in the HIV population and the risk of T2DM is higher in
HIV compared to non-HIV [52,53]. Studies from Africa and Asia also found that the prevalence
of DM was higher among PLHIV compared to the non-HIV population [54–57].
Persistent immune activation and chronic low-grade inflammation due to HIV infection
leading to the production of inflammatory cytokines and mediators are reported mechanisms that
associated with increased risk of insulin resistance and T2DM in PLHIV [58]. In addition, scaling
up of ART globally during the last decade allows PLHIV increasing access to ART leading to
increases in life expectancy which increase the subsequent risk of metabolic diseases that are
common in general ageing population [58–64]. Furthermore, commonly used ART such as
protease inhibitor and nucleoside reserve transcriptase inhibitors are associated with metabolic
disturbance, change in body fat distribution, decrease insulin sensitivity and beta-cell dysfunction
due to changes in mitochondria function and adipokines which can increase the risk of T2DM [65–
67].
T2DM comorbidity in PLHIV increases the risk of death and common diabetes, HIV- or
ART-related complications largely due to the synergism between HIV and DM [68–70]. Studies
showed that DM patients with HIV had poor glycemic control and increased incidence of diabetes
complications such as neuropathy and nephropathy compared to non-HIV [71,72]. One study
found that DM patients with HIV compared to non-HIV had a higher risk of increased brain’s
7

white matter hyperintensities, the condition associated with increased risk of stroke, dementia, and
death [73]. In PLHIV, DM increased the risk of neurocognitive disorder and dementia in ageing
HIV patients compared to those without DM [74,75]. DM found to be a risk factor for renal side
effect among PLHIV on tenofovir, a commonly use ART [76,77]. In addition, DM was an
independent risk factor for increased HIV-related chronic renal disease compared to those who did
not have DM [78–80]. Hence, there is a need to integrate screening, prevention and management
T2DM morbidity in HIV care which is not being addressed in the routine HIV clinical care in
many settings [81–86].
1.4 Relationships between type 2 diabetes mellitus and tuberculosis
Epidemiological studies have shown that there is an increased co-prevalence of T2DM and
TB posing challenges in TB control, especially in low- and middle-income countries [87]. The
prevalence of T2DM among TB patients ranged from 1.8 to 54%, and the prevalence of TB among
T2DM patients ranged from 0.1 to 36 % [88–91]. The country-level analysis done for 163 countries
showed that both TB incidence and prevalence increased in countries with increased T2DM
prevalence during ten years [92]. Although the risk of TB in people living with T2DM is not as
high as in PLHIV, TB cases attributable to DM is higher than to HIV due to the rapid increase of
T2DM epidemic worldwide [27]. The estimated population attributable fraction of TB cases due
to T2DM ranged from 10% to 20%, and the estimated TB cases contributed by T2DM was
1,042,000 in 2012 [93].
T2DM increases the risk of TB disease by two- to four-fold [91]. Hyperglycemia during
T2DM is associated with a dysfunctional innate and adaptive immune responses of T2DM patients
to Mtb [94,95]. Many immunological studies using animal and human models suggested that
8

impairs in phagocytic activity of alveolar macrophage and delayed innate and adaptive immune
responses increase the risk of TB infection, the low level of pro-inflammatory cytokines required
to restrict the Mtb growth increases the risk of progression from TB infection to disease and the
dysfunctional immunity to Mtb increase risk of poor TB treatment outcomes in patients with
T2DM [96–99]. Some studies also suggested that underperforming innate immunity followed by
a hyper-reactive cellular response to Mtb during TB disease might contribute to more lung tissue
damage and more adverse clinical outcomes in TB patients with DM [100].
On the other hand, there is a plausible mechanism by which TB disease may increase the
risk of T2DM [101,102]. Early evidence indicates that TB disease increases the risk of stress
hyperglycemia, a state of transient hyperglycemia induced by the acute illness of TB disease and
reversion occurs after anti-TB treatment [103–105]. Persistent systemic inflammation, proinflammatory cytokine signaling, and elevated stress hormones during TB disease can lead to
increased insulin resistance and stress hyperglycemia, and in some patients may induce overt
T2DM [101].
Most of the epidemiological studies to date examine the impact of T2DM or hyperglycemia
on TB disease outcomes. Many observational studies showed that among patients with TB disease,
T2DM and hyperglycemia increase the risk of poor TB treatment outcomes including delayed
culture conversion, death, and relapse [97,106–109]. The findings on the risk of mortality among
TB/DM patients is mixed as some studies suggested higher mortality among TB/DM patients
compared to non-DM patients, [110–112] however, few studies suggested that the risk of mortality
was not different or lower in TB/DM patients [106,113,114]. Nonetheless, there is strong evidence
indicating that TB patients with DM experience a severe form of TB, such as more lung cavitation
and hemoptysis [107–109]. In addition, T2DM is associated with unfavourable outcomes of TB
9

treatment as more drug-resistant TB, delayed weight gain and a lower increase in haemoglobin
level were reported among TB patients with DM [112,115–118].
In contrast, there is a very few epidemiological studies examine the potential
epidemiological and clinical impact of TB on the risk of T2DM although there are plausible
immunometabolic mechanism that TB disease can increase the risk of hyperglycemia and T2DM
[102].
1.5 Gaps of knowledge on comorbidities of TB and T2DM among PLHIV
The emerging syndemic of HIV, TB, and T2DM is further complicated due to the
interaction among them. In 2013, Oni et al. highlighted the importance of synergism between three
diseases and the neglected priority in research on this issue. He suggested a list of priority research
including to investigate the strength of the interaction between TB and T2DM in people with HIV
and to assess the potential for active screening for TB in people with T2DM and HIV [119]. Later,
in 2015 and 2018, Harries et al. highlighted the emerging epidemic of these three diseases in low
and middle-income countries and also called the scientific community to recognize the importance
of interaction between these three diseases and accelerate the research on comorbidities. In
addition, the authors suggested the integrating the care and treatment for HIV, TB and T2DM for
preventing and early diagnosis of TB and DM and improving the treatment success rate and
outcome of the three diseases [4,120]. Furthermore, in the research agenda addressing the
converging epidemic of TB and DM by Critchley et al. in 2017, the research to address interactions
between TB, DM and HIV was included as an important priority because there was a growing
epidemic of DM in sub-Saharan countries where the prevalence of HIV was high [121].
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However, there are limited numbers of research that studied these three diseases together
and little is known about the strength, casual direction and mechanism of association between
T2DM and TB among PLHIV. We conducted a literature search in PubMed, Google Scholar and
the Cochrane Systematic Review using the search term “tuberculosis AND HIV AND [diabetes
mellitus OR hyperglycemia]” and found 334 articles from the database search. After screening the
abstracts, there were only 24 articles that discussed or studies on these three diseases together.
Among them, three articles are review articles, 12 articles are research studies with the primary
aim to examine the association between TB and DM in the general population and reported the
association in HIV as a subgroup analysis and nine articles are research studies with the primary
aim to assess the association between TB and DM in PLHIV or TB, DM and HIV together. Among
21 research articles, three of them are systematic reviews and 18 studies are original research (table
1). Hence, there is a major knowledge gap remain regarding the interaction between TB, T2DM
and HIV.
Most of the studies were cross-sectional studies to determine the association between TB
and DM among HIV patients. Hence, the causal direction between DM and TB cannot be
determined from the association observed. All the studies interpreted the observed association as
DM is a predictor for the increased risk of TB among HIV patients based on the already known
causal association among the non-HIV population which is DM as a host risk factor for TB disease.
However, there has been increasing evidence of a plausible mechanism that TB disease may lead
to stress hyperglycemia and increase the risk of DM. None of the studies can determine this reverse
direction due to methodological limitation except the study conducted by Faurholt-Jepsen et al.,
which included C-reactive protein measurement as a proxy for acute phase response and adjusted
for the possibility of stress-induced hyperglycemia due to TB. In addition, the observed
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relationship between DM and TB among HIV from these studies were heterogeneous due to
heterogeneity in measurement of the exposure and the outcome.
Among 18 original research, three studies using longitudinal cohort data. The prospective
cohort study conducted by Achhra at el., assess the association of incidence of TB with DM and
glycemic level among HIV patients. DM was defined by using FBG. However, the authors
acknowledge that not all measurements were FBG due to the study sites’ patient standard of care.
The authors also addressed confounders by including in adjusted model except smoking which
was an important factor associated with both TB and DM.
The second study, a retrospective cohort study conducted by Moreira et al., assess the effect
of hyperglycemia during TB treatment on TB treatment outcome and 1-year mortality among
HIV/TB patients. Hyperglycemia was defined using FBG measured at two times during TB
treatment. The findings showed that patients with hyperglycemia had a higher risk of adverse TB
treatment outcome and mortality (adjusted HR: 3.7, 95%CI: 2.2-6.8). However, possible
confounders such as ART use, smoking, BMI were not included in the adjusted model. The authors
also analyzed the changes of the glycemic level after 36 months of mean follow up (SD: 24
months) and found that 22 patients out of 49 hyperglycemic patients during TB treatment
developed DM while one of 414 euglycemic developed DM.
The third study was a retrospective cohort study which we conducted in Myanmar to assess
the association between hyperglycemia at enrollment and risk of all-cause mortality in PLHIV and
whether the relationship is differed by TB status. We found that there was an interaction between
hyperglycemia and TB on the risk of mortality in PLHIV. In TB patients, hyperglycemia was not
a significant risk factor for mortality (adjusted HR, 1.0; 95% CI, 0.8–1.2) although hyperglycemia
12

was a risk factor for mortality among non-TB patients. As the study used RBG as a measure of
hyperglycemia and no information on DM status and DM medications, there was a risk of
measurement bias and there is no clear conclusion can be drawn how TB and DM or hyperglycemia
interact in HIV patient.
According to our systematic literature search, there is not enough study to conclude the
strength of association, causal relationship and interaction between TB and T2DM among HIV
patients. In addition, evidence regarding the role of TB-induced hyperglycemia in PLHIV is
critically missing. Furthermore, a limited number of longitudinal studies to assess the role of
T2DM and hyperglycemia on the clinical outcome of TB and HIV. Hence, empirical evidence for
the management of T2DM and hyperglycemia in patients with TB/HIV is lacking, and more
research is urgently needed to reduce the risk of mortality in HIV/TB patients comorbid with
hyperglycemia and T2DM.
1.6 Gaps of knowledge on comorbidities of HBV/HCV and T2DM in PLHIV
There are studies suggesting that HCV co-infection significantly increased the risk of
T2DM especially in HIV patients with HCV viremia [122,123]. Underlying mechanism of
increased risk of T2DM in patients with HCV include the extrahepatic effects of HCV infection
on endocrine, HCV replication in extrahepatic cells, a heightened immune reaction with systemic
effects or the HCV treatment causing insulin resistance and hyperglycemia [123–126].
Comorbidity with HCV and T2DM also increased risk of cardiovascular events and deaths [127].
Studies also suggested that successful HCV therapy decreased the adverse outcomes and mortality
related to T2DM in patients with HCV [128]. However, there is no information on the risk of
mortality related to HBV and T2DM or hyperglycemia in HIV population.
13

1.7 Statement of purpose
The overall goal of this dissertation is to support the understanding of the association
between chronic infectious - TB, HBV and HCV coinfection, and non-infectious disease - T2DM
comorbidities on the HIV clinical outcomes. To achieve this goal, the following three
observational studies were conducted in a cohort of PLHIV in Myanmar, a country which has a
high burden of all the diseases mentioned. Like in many resource-limited and high HIV burden
countries, gold standard T2DM screening using glycated hemoglobin or fasting blood glucose is
not implemented in Myanmar due to limited resources. However, random blood glucose is usually
measured at enrollment to HIV care and we used random blood glucose measurement as a proxy
to the glycemic level of patients.
Study 1 assessed the biological interaction between low BMI and hyperglycemia with the
risk of TB disease in PLHIV. This study will help to identify the high-risk group of TB disease in
PLHIV to target public health and clinical interventions to effectively use limited resources to
reduce the TB burden in PLHIV.
Study 2 estimated the association between active TB with all-cause mortality, change in
CD4 cells and virological failure after one year on ART and also assessed whether blood glucose
level mediates the association between active TB and all-cause mortality among PLHIV. While
there is a growing knowledge of mechanism of association between TB and hyperglycemia with
mortality in general population, this study presents the finding from HIV population.
Study 3 examined the association between HBV and HCV coinfection with all-cause
mortality in PLHIV and whether the association between HBV and HCV coinfection with allcause mortality in PLHIV varied by hyperglycaemia status. This study will inform the excess risk
14

of mortality due to hepatitis B and C coinfection and hyperglycemia. To date, there is no
information on association between HBV and/or HCV and hyperglycemia with mortality in
PLHIV. Collectively, the three studies presented in this dissertation will contribute new knowledge
to inform the clinical and public health guideline for prevention, screening, diagnosis and
management of comorbidities in PLHIV to reduce mortality.
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Table 1: Summary of studies that report findings on HIV, TB and T2DM or hyperglycemia together
Title of the study

Year
of
study

Objectives

Study design

Study
population
and sample
size

Outcomes

Results

1

Tuberculosis and diabetes in
Guyana[129]

2011

To estimate the
prevalence of DM in
TB

Crosssectional

100 TB
patients

DM measured
by RBG

14% of TB patients had DM, and
none of the DM patients had
HIV.

2

Diabetes is a Risk Factor for
Pulmonary Tuberculosis: A

20062009

To assess the
Case-control
association between
diabetes and TB and
the role of HIV as an

803 TB cases DM measured
and 350 non- by FBG,
TB
OGTT
neighbourhoo
d control

After adjusting for potential
confounders, there was an
association between TB and DM
(aOR: 4.2, 95% CI: 1.5-11.6) but
the association between TB and
DM was not observed in HIV
infected patients (aOR: 0.1, 95%
CI: 0.01-1.8).

Case-Control Study from
Mwanza, Tanzania[130]

effect modifier,

3

Important co-morbidity in
patients with diabetes
mellitus in three clinics in
Western Kenya[131]

20072011

To determine the
prevalence of DM
patients with a
history of TB and
HIV

Crosssectional

1376 DM
patients

TB and HIV

33 (2%) patients had a history of
TB before DM diagnosis and 44
(3%) had TB after DM
diagnosis. Among 44 DM
patients who had TB, 5(17%)
were HIV positive and TB/
DM/HIV comorbidity was 1%.

4

Overt diabetes mellitus
among newly diagnosed

20112012

To determine the
prevalence of DM
among TB patients

Crosssectional

260 TB
patients

DM measured
by FBS

208 patients were HIV coinfected. DM prevalence among
TB was 8.5% (22 patients). In
adjusted analysis, HIV
coinfected patients had lower
odds of having DM (OR=0.17,
95% CI 0.06-0.51).

Ugandan tuberculosis
patients: a cross-sectional
study[132]
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5

Relationship between
hyperglycemia and the risk
of tuberculosis in Asian HIV
positive individuals in the

20052010

To determine the
relationship between
glycemic level
(FBG) and TB in
HIV

Prospective
cohort

4,617 HIV
patients

TB disease

TB incidence was 1.58/100
person-years
There was a higher risk of TB
among DM patients compared to
non-DM (Adjusted HR:1.34
(IQR 1.01-1.79)).

antiretroviral therapy era:
cohort study[133]
6

Screening for diabetes
mellitus and human
immunodeficiency virus
infection in persons with
tuberculosis[134]

20102012

To determine the
prevalence of DM
and HIV in TB
patients

Crosssectional

3,376 TB
patients

DM and HIV

The prevalence of DM was 4.8
% and HIV was 3.5%. The
prevalence of HIV/DM
comorbidity in TB patients was
0.3%.

7

Treatment Outcomes in
Tuberculosis Patients with

20012011

To assess the factors
influencing the
outcome of TB-DM
patients

Analysis of
the result of a
surveillance
system

26,401 TBDM patients

Loss to follow
up and death

The odds of loss to follow up
and death were higher in
HIV/AIDS patients (OR=2.16
and 2.87 respectively)

20112012

To assess common
opportunistic
infections among
HIV/DM patients

Case-control

37 PLHIV
with DM as
cases and 37
PLHIV
without DM
as control

Pulmonary
and
extrapulmonar
y TB disease

Prevalence of TB was not
significantly different between
PLHIV-DM and PLHIV without
DM

5849 TB
patients

Prevalence of
DM

Diabetes: A Polytomous
Analysis Using Brazilian
Surveillance System[135]
8

Opportunistic Infections
among People Living
with HIV (PLHIV) with
Diabetes Mellitus (DM)
Attending a Tertiary Care
Hospital in Coastal City of
South India[136]

9

Factors associated with
diabetes mellitus among
adults with tuberculosis in a

20002013

To assess the factor
associated with
prevalence DM
among TB

Crosssectional

17

(Extrapulmonary TB:22% in
PLHIV-DM and 34.5% in
PLHIV, Pulmonary TB: 16% in
both group).
Prevalence of DM was 5.9%.

large European city, 2000–
2013[137]

HIV patients had lower odds of
having DM (adjusted OR: 0.27
(95% CI: 0.10-0.57).

10

The diabetes-tuberculosis
co-epidemic: the role of
international migration[138]

20072012

To assess the factor
associated with DM
among TB

Retrospective
cohort

971 TB
patients

Prevalence of
DM diagnosed
using WHO
criteria

DM was diagnosed in 48
patients (5%) before their TB
diagnosis and 15 (2%) during
admission for TB treatment.
Patients with HIV had lower
odds of having DM in TB
patients (OR: 0.2 (95% CI: 0.00.8)

11.

Transient Hyperglycemia in
Patients with Tuberculosis in
Tanzania: Implications for
Diabetes Screening
Algorithms[104]

20122014

To compared DM
screening strategies

Case-control

378 TB cases
and 491 nonTB control
cases

Diagnosed
DM and
hyperglycemia
using FBG,
OGTT and
HbA1c

Higher odds of DM among TB
(OR:6.5, 95% CI: (3.3-12.9).
Stratified by HIV: the OR
among HIV negative was 19.3
and among HIV infected was 4.7
showing association is weaker in
HIV patients (only if measured
by HbA1c)

12

Tuberculosis and diabetes in
Nigerian patients with and
without HIV[139]

2017
(Publi
shed)

To determine the
prevalence of DM
among TB with or
without HIV

Crosssectional

410
hospitalized
presumptive
TB patients

TB and DM
measured by
FBG and
HbA1c

62 (15%) of 113 TB patients had
DM. HIV negative DM patients
had a higher risk of TB than HIV
positive DM patients (aOR 4.3
vs 3.3).
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The change in blood glucose
levels in tuberculosis

2015

To understand

Prospective
cohort

270 patients
on anti-TB
treatment

FBG

Patients with HIV had unstable
blood glucose level during antiTB treatment

patients before and during
anti-tuberculosis
treatment in China[140]

if blood glucose
levels were stable or
fluctuated
during anti-TB
treatment
18

14

Trilateral overlap of
tuberculosis, diabetes and
HIV-1 in a high-burden
African setting: implications
for TB control[141]

20132015

To determine the
association between
TB and
diabetes/impaired
glucose regulation in
the context of HIV-1

Crosssectional

852 patients
with
respiratory
symptom

DM measured
by FBG and
HbA1c and
TB

The prevalence of DM among
414 TB patients was 12.6% and
among 438 non-TB patients was
10.1%. In adjusted analysis,
diabetes was associated with TB
(OR:2.4 (95% CI: 1.3-4.3).
Heterogeneity of association was
found once stratified by HIV
status but the association
between DM and TB was still
strong in HIV-positive patients.
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The prevalence and
determinants of active

20142015

To investigate

Crosssectional

440 DM
patients

Active TB

Active TB prevalence was 3%.
There was no significant
difference in glycemic level
between TB patients and non-TB
cases. HIV was a significant risk
factor associated with active TB
(aOR:11.3, 95% CI: 3.26-39.42).

Retrospective
cohort

473 HIV/TB
patients

DM and
hyperglycemia
measured by
FBG, TB
treatment
outcome and
1-year
mortality rate

Prevalence of hyperglycemia
was 10% and known DM was
2%. The 1-year mortality rate
was significantly higher in
hyperglycemic patients (aHR:
3.72, 95% CI: 2.17-6.38).

the prevalence of
active TB among
DM

tuberculosis among diabetes
patients in Cape
Town, South Africa, a high
HIV/TB burden setting[142]
16

Hyperglycemia during
tuberculosis treatment
increases morbidity and
mortality in a contemporary
cohort of HIV-infected
patients in Rio de Janeiro,
Brazil[143]

20102015

To assess the
prevalence of
hyperglycemia
among HIV/TB
patients on anti-TB
treatment and
compare the TB
treatment outcome
and 1-year mortality
rate according to the
glycemic status of
patients during TB
treatment.
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17

Synergism between diabetes
and human
immunodeficiency virus in
increasing the risk of
tuberculosis[144]

20151016

To study the
Crosssynergism between
sectional
DM and HIV in
increasing the risk of
TB symptoms

7,708

HIV (selfreported or
tested), DM
measured by
RBG and TB
symptoms

DM and HIV patients had a
higher risk of TB symptoms
(aOR 1.36, 95%CI 1.11–1.67
and aOR 1.66, 95%CI 1.40–1.97
respectively). There was an
interaction between HIV and
DM on the multiplicative scale.
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Hyperglycemia and risk of
all-cause mortality among

20112017

To assess the
association between
hyperglycemia at
enrollment and risk
of all-cause
mortality in PLHIV
and whether the

25,851 HIV
patients

Hyperglycemi
a measured by
RBG at
enrollment)
and all-cause
mortality

Hyperglycemic patients had a
higher risk of mortality (adjusted
HR, 1.1; 95% CI, 1.0–1.3).
There was an interaction
between hyperglycemia and TB
in association with mortality. In
TB patients, hyperglycemia was
not a significant risk factor for
mortality (adjusted HR, 1.0; 95%
CI, 0.8–1.2).

people living with HIV with
and without tuberculosis
disease in Myanmar (2011–
2017)[145]

Retrospective
cohort

the relationship is
differed by TB
status

TB: tuberculosis; DM: diabetes mellitus; RBG: Radom blood glucose; FBS: Fasting blood glucose; OGTT: oral glucose tolerance test; OR odds ratio;
aOR: adjusted OR; HR: hazard ratio; aHR: adjusted HR;
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ABSTRACT
Background
Low body mass index (BMI) and hyperglycemia are each establish risk factors for tuberculosis
(TB) disease among people living with HIV (PLHIV); however, there is limited understanding
how these factors interact. We estimated biological interaction between low BMI and
hyperglycemia with the risk of TB disease among PLHIV.
Methods
PLHIV (≥15 years old) who had records of random blood glucose (RBG), weight and height
measurements at enrollment to Integrated HIV Care Program, Myanmar, 2011-2017 were eligible.
Exclusion criteria were receiving TB treatment before enrollment or receiving isoniazid TB
preventive therapy or multi-drug resistant TB treatment during follow-up. The outcome was
incident TB, defined as patients starting first-line TB treatment during follow-up. We used Cox
proportional models to estimate the interaction between low BMI (BMI ≥18.5 kg/m2) and
hyperglycemia (RBG ≥140 mg/dl) on the risk of TB disease.
Results
Among 41,179 PLHIV enrolled, 20,865 patients met eligibility criteria. The median age was 36
years (range 15-91 years), 55% were male, 36% had low BMI, 6% had hyperglycemia. During the
median follow-up of 2.2 years (IQR: 0.5,4.2), the incidence of TB was 6.7 per 100 person-years.
Patients with low BMI or hyperglycemia had a higher hazard rate of TB compared to their
counterpart [adjusted HR (aHR): 1.41 (95% CI: 1.32, 1.51) and 1.17 (95% CI: 1.03, 1.32),
respectively]. In interaction analysis, patients with joint exposure to low BMI and hyperglycemia
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had the highest hazard rate of incident TB compared to those with no exposure [aHR: 1.84 (95%
CI: 1.55, 2.18)] and the relative excess risk (of TB disease) due to the interaction of two exposures
was 0.42 (95% CI:0.07,0.78).
Conclusions
PLHIV with low BMI and hyperglycemia represent a subgroup with high risk of TB incidence.
There is a need to assess if TB preventive treatment, nutritional support, and hyperglycemia
management can reduce TB incidence in this joint exposed group.
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BACKGROUND
Among people living with Human Immunodeficiency Virus (PLHIV), tuberculosis (TB)
disease is a major opportunistic infection and the leading cause of death. Globally, 251,000 deaths
among PLHIV in 2018 were attributed to TB disease [146]. Comorbidity with TB disease poses
substantial challenges in the clinical management of HIV and threatens the global public health
goals of reducing morbidity and mortality among PLHIV [33,34]. Most of the countries affected
by the dual burden of TB and HIV are resource-limited countries. Therefore, identification of
subgroups to target public health and clinical interventions is urgently needed to effectively use
the limited resource to reduce the TB burden among PLHIV.
Low BMI (BMI <18.5 kg/m2) is a known risk factors for TB disease in PLHIV [147–149].
Another factor associated with increased risk of TB disease is type 2 diabetes mellitus (T2DM)
and hyperglycemia (high glycemic level in people with or without T2DM) [133,150]. To date,
most data regarding hyperglycemia and TB risk come from patients without HIV [150–152]. Low
BMI and hyperglycemia are common in PLHIV [57,153–155]. About 30% of PLHIV in resourcelimited countries were low BMI [20,156]. About 20% of PLHIV were reported to be
hyperglycemia (fasting blood glucose >110mg/dl) [57]. Therefore, it is important to understand
and assess the biological interaction between low BMI and hyperglycemia in PLHIV to identify
the subgroup with increased risk of TB disease to target interventions that could reduce risk of TB
disease among them.
To determine the subgroup, biological interaction between the two risk factors can be
measured by partitioning the risk among those with joint exposure from those with exposure to
either risk factor separately [157,158]. The joint effect of BMI and T2DM on TB disease in nonHIV population had been studied in different settings [159–161]. All the studies showed that there
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was a joint effect of BMI and T2DM on the risk of TB disease, although the direction of the
associations was contradicting among studies. A cross-sectional study from India found that the
highest risk of TB disease was observed among participants with overweight or obese and T2DM
compared to those without diabetes with normal weight [159]. However, a cohort study from
Taiwan showed that underweight individual with T2DM had a higher risk of TB disease compared
to an individual with normal weight and without T2DM [160]. Similarly, a recent study from
Singapore showed that underweight individuals with T2DM had the highest risk of TB disease
compared to an obese individual with diabetes mellitus [161]. We can make an inference from the
latter two studies that underweight and T2DM may have synergistic interaction on the risk of TB
disease.
To date, there is a lack of information regarding the interaction between low BMI and
hyperglycemia among PLHIV. In many resource-limited and high HIV burden countries, gold
standard T2DM screening and glycemic level measurement using glycated hemoglobin or fasting
blood glucose is not implemented due to limited resources. However, random blood glucose is
usually measured at enrollment (the time of entry to HIV care) or at the start of antiretroviral
therapy (ART) which can be used as a proxy to the glycemic level of patients. Therefore, we aimed
to assess the biological interaction between low BMI and hyperglycemia at enrollment on the risk
of TB disease among PLHIV from Myanmar.

METHODS
Study Design
This was a cohort study using secondary program data.
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Study Setting, sources of data and data collection
Myanmar, with a population of 52 million, is one of the 30 high tuberculosis burden
countries. Tuberculosis and HIV remain two major public health problems in Myanmar. In 2018,
there were 212,000 PLHIV in Myanmar and the TB incidence was 338/100,000 population with
about 15,000 people co-infected with TB and HIV [3,146].
The country office of the International Union Against Tuberculosis and Lung Disease (a
non-governmental organization) and the National AIDS Program (NAP) are jointly implementing
Integrated HIV Care Program for providing HIV treatment and care to PLHIV in the public health
sector in 5 regions of the 15 regions of the country. In 2018, there were 49 HIV clinics under the
program. The details of the services provided at the HIV clinics under the IHC program were
described in detail elsewhere [162].
All PLHIV enrolled for HIV care in the clinics receive weight, height, random blood
glucose (RBG), CD4 count, hemoglobin measurement and TB disease screening. They also receive
screening of TB disease during quarterly follow-up visits. Patient outcomes were recorded as
regular follow-up (attending clinic appointment regularly), death (patient’s family or the outreach
workers reported to the clinic that the patient had died), lost to follow-up (not attending the clinic
within three months after the scheduled appointment date) and transferred out (patient was
transferred out to other HIV care program). Date of death was recorded from hospital records if
patients died at the hospital or as reported by families if the patient died at home. At every visit,
patients’ data were recorded on paper-based patient medical records by medical officers and
entered into an electronic database by data entry operators. For this study, data of patients who
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enrolled between January 2011 and August 2017 with their follow-up and outcome data until 31st
August 2018 were extracted from the electronic database.
Study population
PLHIV ≥15 years who enrolled to Integrated HIV Care Program between January 2011
and August 2017 and who had records of RBG, weight and height measurements at enrollment
were eligible. Exclusion criteria were age younger than 15 years, receiving TB treatment before
enrollment or receiving isoniazid TB preventive therapy or treatment for multi-drug resistant TB
during follow-up and not having a record of enrollment random blood glucose, weight and height
measurements.
Data variables
The first exposure of interest in this study was BMI at enrollment calculated from
enrollment weight and height. Patients with BMI <18.5 kg/m2 are categorized as low BMI or
underweight, 18.5–23 kg/m2 as normal, 23–27.5 kg/m2 as overweight and >27.5 kg/m2 as obese as
per WHO guideline [163]. The BMI was also categorized into low BMI (<18.5 kg/m2) and
normal/high BMI (≥18.5 kg/m2) groups.
The second exposure of interest was an RBG level measured by glucometer using capillary
blood at enrollment. RBG ≥140 mg/dl measured at enrollment was defined as hyperglycemia
according to previous studies and WHO 2-hour postprandial blood glucose classification for
diagnosis of prediabetes [164–166]. RBG level was also categorized into four categories <110,
100-139, 140-199 and >199 mg/dl.
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The outcome of interest was incident TB. Incident TB was defined if the patient was on
TB treatment (either for pulmonary or extra-pulmonary) between the date of enrollment and date
of death, loss to follow-up, transferred out or of end of study (31st August 2018). TB disease was
diagnosed in this setting using sputum smear microscopy, X-pert MTB/Rif assay and/or chest Xray if the patient has any TB disease symptoms. TB disease was also diagnosed clinically when
the patients had symptoms suggestive of TB even if the diagnostic investigations were negative.
All the diagnosed TB patients were immediately treated unless they died or were lost to followup.
Covariates included age, sex, marital status, employment, literacy status (literate or
illiterate), alcohol consumption (never, weekly or daily), ART status, weight, height, hepatitis B
surface antigen, anti-hepatitis C antibody, baseline CD4 cell count (cells/mm3) and anemia
measured at enrollment. Anemia was categorized based on hemoglobin levels: normal (male, ≥13
g/dl; female, ≥12 g/dl), mild (male, 11–12.9 g/dl; female, 11–11.9 g/dl), moderate (both sexes,
8.0–10.9 g/dl) and severe anemia (both sexes <8.0 g/dl).
Analysis and statistics
Enrolment characteristics of patients were compared between eligible and excluded group
and across BMI categories using Chi-square test. Rate of TB disease during the follow-up was
calculated by dividing the number of TB cases by person-years follow-up. Person-years of followup was calculated from the date of enrolment to the date of TB treatment initiation, death, lost to
follow-up, transferred out or 31st August 2018 (censor date). Cox proportional hazard models were
used to estimate the hazard ratios and 95% confidence interval (CI) to determine factors associated
with incident TB. Nelson-Aalen cumulative hazard estimates were used to plot the cumulative
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hazard of incident TB during follow-up, stratified by BMI categories and hyperglycaemia status.
We fitted models using BMI and blood glucose level as a continuous predictor, a categorical
predictor and a restricted cubic spline with 4 knots. Proportional hazard assumption was checked
using log-log survival curve, and goodness-of-fit was assessed using Schoenfeld residuals. To
assess interaction, we calculated the rate of TB, incidence rate differences and the adjusted hazard
ratio for each exposure level. We controlled potential cofounders for both exposures based on
bivariable analysis and directed acyclic graph theory. Then, we estimated the relative excess risk
due to interaction (RERI), the attributable proportion due to interaction and synergy index along
with their 95% CI using the icp command in STATA [157,158]. With the assumptions that both
exposures have positive monotonic effects, i.e. they are never preventive for any individual, and
cofounders are controlled for both exposures, RERI >0 indicates that there is a biological
interaction, an excess risk of disease due to the interaction between two exposures [158] .
Attributable proportion measures the proportion of disease in the joint exposure group due to
biological interaction between the two conditions. Synergy index >1 indicates that there is a
biological interaction between two conditions.
We also performed sensitivity analyses. First, as smoking status was an unmeasured
confounder, e-values were estimated to assess the minimum strength of the association that the
smoking status would need to have with both the exposure and the outcome to shift the estimate
to null [167]. We also calculated the adjusted hazard ratio using different strength of association
between smoking and each exposure [168]. Second, to assess bias due to exposure
misclassification, we calculated the relative risk of TB disease associated with each exposure using
different sensitivity and specificity of the measurement [168]. Third, patients diagnosed with TB
during the first three months of enrolment can be those who already had TB disease at enrolment
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(prevalent TB). Hence, we also fit the models after excluding patients with TB disease diagnosed
within three months of enrolment. Finally, patients who died or were lost to follow-up before the
event (incident TB) could be a competing risk. Hence, we estimated adjusted hazard ratio using a
cause-specific model as well as a sub-distribution hazard model. STATA (version 14 Stata Corp
LP USA) was used for all analyses.
Ethical considerations
The study proposal was approved by the Union Ethics Advisory Group (Paris, France), Ethics
Review Committee at the Department of Medical Research, Ministry of Health and Sports
(Yangon, Myanmar) and Institutional Review Board at Georgia State University (Atlanta, USA).
Permission to conduct the study was also obtained from The National Tuberculosis and HIV/AIDS
Program, Department of Public Health, Ministry of Health and Sports Myanmar

RESULTS
Of 41,179 PLHIV enrolled during the study period, 20,865 PLHIV met inclusion criteria
and were included in this analysis (Supplemental Figure 1). Enrollment characteristics between
patients included and those excluded in the study were presented in Supplemental Table 1. The
median age (interquartile range (IQR)) of the study cohort was 36 (30-42) years, 55% were male,
1,324 (6%) had hyperglycemia, 7,610 (37%) had low BMI at enrollment. Notably, patients older
than 45 years, male, patients with CD4<200 cells/mm3 and those with severe anemia
disproportionately had low BMI at enrollment Supplemental Table 2. More patients in the
hyperglycemic group (9%) were obese compared to the euglycemic group (7%).
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Patient characteristics associated with risk of TB disease
The median (IQR) follow up duration of the cohort was 2.2 (0.5-4.2) years contributed to
53,880 person-years of follow-up and 17% (n=3,628) developed active TB during the follow-up.
The incidence rate of TB was 6.7 TB cases per 100 person-years [95% CI: 6.5, 7.0]. The factors
associated with active TB are presented in Table 1. Patients who were male [HR:1.75,
(95%CI:1.63,1.88)], 25 to 45 years old [HR:1.43 (95% CI: :1.25,1.64)] or >45 years old [HR:1.39
(95% CI:1.19,1.63)] or underweight [HR: 1.97 (95% CI: 1.83,2.11)] or had hyperglycemia
[HR:1.22 (1.08,1.39)] had a higher risk of TB disease. Other risk factors for TB disease included
history of alcohol drinking, lower CD4 cell count, WHO clinical staging 3 or 4 and having anemia.
Being on ART prior to enrollment was associated with a lower risk of TB disease [HR:0.30 (95%
CI:0.23,0.40)].
Risk of TB disease by body mass index and glycemic status
The estimated cumulative incidence of active TB was highest in patients with low BMI in
both glycemic levels (Figure 1.a and 1.b). The differences in the incidence rate of active TB
between patients with low BMI and those with BMI (≥18.5 kg/m2) were shown in Table 2. One
unit increase in BMI reduced the hazard rate of TB disease by 3% [aHR 0.97 [95% CI: 0.96, 0.98].
When BMI was included as a dichotomous predictor in the model, the aHR was 1.41 [95% CI:
1.32, 1.51] in patients with low BMI compared to those with normal or high BMI. When BMI was
included as a restricted cubic spline in the model, aHR was 1.30 [95% CI: 1.19, 1.42] in patients
with BMI 18.5 kg/m2 compared to patients with BMI 23 kg/m2. The estimated HR of incident TB
using the restricted cubic spline regression was plotted across BMI in Supplemental Figure 2.a.
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The differences in incidence rate of active TB between different glycemic level was shown
in Table 2. The adjusted hazard of risk of TB disease was 1.17 [95% CI: 1.03, 1.32] in
hyperglycemic patients compared to patients with euglycemic level. When blood glucose level
was included as a restricted cubic spline in the model, the adjusted hazard of risk of TB disease
was 1.05 [95% CI: 1.00, 1.10] in patients with blood glucose level 140 mg/dl compared to patients
with blood glucose 110 mg/dl. The estimated hazard ratio of the risk of TB using the restricted
cubic spline regression was plotted across blood glucose level in Supplemental Figure 2.b.
Biological interaction between low BMI and hyperglycemia
The rates of TB disease and adjusted hazard ratios of each dichotomous exposure level of
low BMI and hyperglycemia were presented in Table 3. Patients with low BMI and hyperglycemia
had the highest risk of active TB compared to those with BMI ≥18.5 kg/m2 and RBG <140 mg/dl
[adjusted HR: 1.84 (95% CI:1.55, 2.18)].
RERI was 0.42 (95% CI:0.07,0.78), the attributable proportion was 0.23 (95% CI: 0.06,
0.36) and synergy index was 2.01 (95% CI: 1.09, 3.74) using the adjusted hazard ratios from the
above model. As both low BMI and hyperglycemia was associated with increased risk of TB
disease (positive monotonic effects) and assuming all the potential confounders were controlled
for both exposures, the RERI >0 and synergy index >1 indicate that there is a biological interaction
between low BMI and hyperglycemia on the risk of TB disease.
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DISCUSSION
Identification of subgroups with a high risk of TB disease is important to effectively
allocate the public health resources to target the intervention to reduce the TB-related morbidity
and mortality in PLHIV. To our knowledge, this is the first study to identify the subgroup with a
high risk of TB disease among PLHIV by assessing the biological interaction between low BMI
and hyperglycemia by partitioning the effect by each exposure level. Our study suggests that
patients who were simultaneously underweight and hyperglycemic had a relative excess risk of
TB due to joint exposure compared to exposure to either condition alone. The estimated risk of TB
disease in patients with joint exposure to low BMI and hyperglycemia was 2.7 times higher
compared to those who did not have any exposure. The risk in underweight patients with normal
glycemia was 1.7 compared to those who did not have any exposure. We also found that the
attributable proportion of TB disease due to biological interaction or joint exposure was 33%.
Other important findings include more than one-third of the PLHIV had low BMI at the time of
enrollment and habitual alcohol drinkers were more likely to have low BMI and had a higher risk
of TB diseases.
Our results are similar to studies conducted in the non-HIV population in Asia setting. The
study conducted in Taiwan by Lin et al. showed that there was a joint effect of BMI and T2DM
on the risk of TB disease [160]. Of two prospective cohort included in their study, the result from
one of the cohorts showed that participants who were underweight and had diabetes had the highest
risk of TB compared to other levels of exposures. However, this joint effect was not detected in
the other cohort included in the study. One of the limitations of their finding was that weight,
height and T2DM status were ascertained from self-reported information. Another recently
published study from Singapore also showed a very high risk of TB disease among underweight
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individuals with T2DM compared to obese without T2DM (adjusted HR:8.3). Similarly, the
Singapore study also used self-reported information for exposure ascertainment.
On the contrary, the cross-sectional study conducted in India by Kubiak et al. showed that
individuals with T2DM and obesity had the highest prevalence of TB disease compared to people
without T2DM and normal weight (adjusted prevalent ratio: 12.0) [159]. In their study, the
adjusted prevalence ratios were similar between individuals who were underweight with T2DM
and those who were in low BMI group with no T2DM. This contradicting finding can be in part
explained by the difference in study design and the definition of T2DM exposure. Although the
previous studies assess the joint effect of BMI and T2DM on the risk of TB, none of them
calculated the quantitative measure for biological interaction such as RERI and attributable
proportion due to joint exposure.
Similar to many resource-limited high HIV and TB burden countries, a substantial number
(36%) of PLHIV in our cohort had low BMI at the time of enrollment. Many of the cohort studies
from Asia and Africa reported that the proportion of adult PLHIV with underweight was about 2834% [156,169–171]. Improving access to ART globally over the last decades shift PLHIV being
underweight to a healthy weight as a result of starting ART earlier, preventing opportunistic
infections and better immune recovery. However, PLHIV from many developing countries present
to the health system late due to stigma and other factors related to socioeconomic status. A study
from Uganda showed that food assistance improved BMI and reduced the proportion of
underweight among PLHIV over the 12 months [172]. As underweight is a proxy for poor
nutritional status, intervention such as nutritional supplementation and food security program for
PLHIV should be considered in those setting in addition to early HIV diagnosis and ART [173].
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One of the strengths of the study is having a large sample size with adequate follow-up
time providing the opportunity to assess the risk of TB disease and allow us to make inference on
the temporal association between hyperglycemia and underweight at enrollment and TB disease
during follow-up. Exposure and outcome measures were relatively robust as we used the clinical
data where random blood glucose, weight and height were measured by the clinic staffs and records
in the individual medical record. We controlled for important confounders for exposures and
outcome association such as age, sex, CD4 cell and ART status.
Limitations of the study include potential exposure misclassification as we used random
blood glucose measurement to define hyperglycemia which has limited validity than fasting blood
glucose measurement. We calculated relative risks (RR) of risk of TB associated with
hyperglycemia using sensitivity and specificity of hyperglycemia measurement range from .80 to
.99. The observed RR of risk of TB among patients with hyperglycemia was 1.51. From the
sensitivity analysis, the point estimate for RR range from 0.15 to 3.07. Another limitation is that
there is no information on diabetes diagnosis and treatment after the random blood glucose
measurement and during the follow-up. There could be patients who were on anti-diabetes
medications and successfully controlled their glycemic level which could shift over observed
associated toward or away from null.
In addition, we did not have data on cigarette smoking history which is a known risk factor
for T2DM and TB disease. To address this unmeasured cofounder, we calculated e-value and
estimated the range of hazard ratios using different bias parameters. The e-value for the association
between low BMI and risk of TB is 1.82 and e-value for the association between hyperglycemia
and risk of TB was 1.64 showing that only if there is a strong association between unmeasured
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confounder (smoking) and both exposure and outcome could shift our observed association toward
null.
Another limitation is the potential selection bias as about 50% of the patients enrolled
during the study period did not have blood glucose, weight and height measurement were excluded
from the analysis. However, the demographic and clinical characteristics of patients who were
included and those who were excluded from the analysis are similar and we believe that our
observed estimates are generalizable.
Despite the limitations, our study results have many public health and clinical implications.
First, we identified the PLHIV subgroup which has the highest risk of TB disease. As Myanmar is
a resource-limited country, intervention to prevent TB disease such as providing isoniazid therapy
can be considered to prioritize in the group with the highest risk. In addition, there is a need to
assess if interventions such as providing a nutritional supplementation to improve weight gain and
optimal control of hyperglycemia and T2DM can reduce TB incidence in PLHIV especially among
joint exposure group. Finally, as habitual alcohol consumption was associated with underweight
and risk of TB disease, counselling to sober alcohol use may benefit for the patients in preventing
adverse clinical outcomes.

CONCLUSIONS
This study identified the biological interaction between low BMI and hyperglycemia on
the risk of TB disease among PLHIV and the subgroup with joint exposure to prioritize the
intervention to reduce the risk of TB disease. Both low BMI and hyperglycemia were associated
with the risk of TB disease. Patients who simultaneously had low BMI and hyperglycemia
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experienced about 23% excess risk due to joint exposure than those who had low BMI or
hyperglycemia alone. The results highlight to consider the implementation of TB preventive
therapy, nutritional supplement intervention and screening of hyperglycemia and T2DM among
PLHIV and if the resource-limited, the interventions should be prioritized for joint exposure group.
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Table 1. Patient characteristics associated with incident TB among people living with HIV enrolled Integrated HIV Care
Program, 2011-2017, Myanmar

Characteristics*
Age (year)

Sex
BMI (kg/m2)

RBG (mg/dl)

Alcohol drinking

CD4 cell count (cells/mm3)

WHO clinical staging
Anemia

Total
<25
25-45
>45
Male
Female
<18.5
18.5-22.9
23-27.5
>27.5
<140
(euglycemic)
≥140
(hyperglycemia)
Never
Habitual (daily)
Social (weekly)
Not recorded
>350
200-349
<200
unknown
Stage 1 or 2
Stage 3 or 4
No
Mild or Moderate
Severe

Personyears
53880
4065
41929
7886
26594
27287
16801
23980
8878
4223

Incident TB
3628
215
2848
565
2427
1201
1901
1206
319
202

50981

3361

2900
38956
3008
11079
837
12181
14844
26792
64
33244.89
20635.934
22624
28819
2009

267
2102
449
1012
65
381
601
2611
35
852.0
2776.0
628
2444
515
39

IR [95% CI]
6.7
5.3
6.8
7.2
9.1
4.4
11.3
5.0
3.6
4.8

[6.5,7.0]
[4.6,6.0]
[6.5,7.0]
[6.6,7.8]
[8.8,9.5]
[4.2,4.7]
[10.8,11.8]
[4.8,5.3]
[3.2,4]
[4.2,5.5]

6.6 [6.4,6.8]
9.2
5.4
14.9
9.1
7.8
3.1
4.0
9.7
54.4
2.6
13.5
2.8
8.5
25.6

[8.2,10.4]
[5.2,5.6]
[13.6,16.4]
[8.6,9.7]
[6.1,9.9]
[2.8,3.5]
[3.7,4.4]
[9.4,10.1]
[39,75.7]
[2.4,2.7]
[13.0,14.0]
[2.6,3.0]
[8.2,8.8]
[23.5,27.9]

HR [95% CI]
ref
1.43
1.39
1.75
ref
1.97
ref
0.74
0.93

[1.25,1.64]
[1.19,1.63]
[1.63,1.88]
[1.83,2.11]
[0.65,0.84]
[0.80,1.08]

ref
1.22 [1.08,1.39]
ref
2.1
1.4
1.06
ref
1.44
3.18
3.39
ref
4.65
ref
2.85
6.12

[1.90,2.33]
[1.30,1.51]
[0.83,1.36]
[1.27,1.64]
[2.86,3.54]
[2.39,4.79]
[4.30,5.02]
[2.61,3.12]
[5.44,6.87]

Hepatitis B surface antigen

Hepatitis C antibody

Prior exposure to ART
On ART during follow-up

Not recorded
Negative
Positive
Not recorded
Negative
Positive
Not recorded
No
Yes
No
Yes

428
47062
4311
2508
46665
4684
2532
50376
3505
981
52900

41
3040
304
284
2953
389
286
3554
74
199
3429

9.6
6.5
7.1
11.3
6.3
8.3
11.3
7.1
2.1
20.3
6.5

[7.0,13.0]
[6.2,6.7]
[6.3,7.9]
[10.1,12.7]
[6.1,6.6]
[7.5,9.2]
[10.1,12.7]
[6.8,7.3]
[1.7,2.7]
[17.7,23.3]
[6.3,6.7]

2.09
ref
1.06
0.99
ref
1.06
0.99
ref
0.39
ref
1.14

[1.52,2.87]
[0.94,1.19]
[0.87,1.12]
[0.95,1.18]
[0.88,1.12]
[0.31,0.49]
[0.99,1.32]

IR: incidence rate, HR: hazard ratio; BMI: body mass index; RBG: random blood glucose; ART: antiretroviral therapy
*All characteristics were measured at enrollment to HIV care except the last variable, whether the patient was on ART during followup or not.
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Table 2. Association between body mass index and random blood glucose level with incident TB among people living with HIV
enrolled Integrated HIV Care Program, 2011-2017, Myanmar
IR [ 95% CI]

IR difference [95%CI]

HR [95% CI]

aHR* [95%CI]

11.3 [ 10.8, 11.8]
4.7 [4.4, 4.8]
11.3 [10.8, 11.8]
5.0 [ 4.8, 5.3]
3.6 [3.2, 4.0]
4.8 [4.2, 5.5]
-

6.6 [6.1, 7.2]
Ref
6.3 [5.7, 6.9]
Ref
-1.4 [-1.9, -0.9]
-0.3 [-0.9, 0.05]
-

0.92 [ 0.90, 0.93]
2.11 [ 1.97, 2.25]
Ref
1.97 [1.83, 2.11]
Ref
0.74 [0.65, 0.84]
0.93 [0.80, 1.08]
2.71 [2.48, 2.97]
1.89 [1.73, 2.05]
Ref
0.95 [0.91, 1.00]

0.97 [0.96, 0.98]
1.41 [1.32, 1.51]
Ref
1.44 [1.33, 1.55]
Ref
0.95 [0.84, 1.08]
1.36 [1.17, 1.59]
1.61 [1.46, 1.77]
1.30 [1.19, 1.42]
Ref
1.09 [1.04, 1.14]

6.6 [6.4,6.8]
9.2 [8.2,10.4]
6.3 [6.1,6.5]
8.3 [7.7,9]
9.4 [8.3,10.7]
8.1 [5.9,11.4]
-

Ref
2.6 [ 1.5, 3.7]
Ref
2.0 [1.3, 2.7]
3.1 [1.8, 4.3]
1.8 [-0.9, 4.5]
-

1.00 [1.00, 1.00]
Ref
1.22 [1.08, 1.39]
Ref
1.21 [1.10, 1.32]
1.26 [1.11, 1.45]
1.24 [0.89, 1.73]
Ref
1.06 [1.02,1.11]
1.09 [0.92, 1.29]
1.11 [0.86. 1.43]

1.00 [1.00, 1.00]
Ref
1.17 [1.03, 1.32]
Ref
1.17 [1.07, 1.28]
1.19 [1.05, 1.37]
1.23 [0.89, 1.72]
Ref
1.05 [1.00,1.10]
1.10 [0.93, 1.30]
1.14 [ 0.88, 1.47]

2

BMI (kg/m )
Continuous predictor (increase in one unit of BMI)
Categorical model (Dichotomous)
<18.5 (Low)
≥18.5 (Normal/high)
Categorical model (4 level)
<18.5 (Low)
18.5-22.9 (Normal)
23-27.5 (Overweight)
>27.5 (Obese)
Restricted cubic spline
16.0
18.5
23.0
27.5
Random Blood Glucose (mg/dl)
Continuous predictor (increase in one unit)
Categorical model (Dichotomous)
Euglycemia (<140)
Hyperglycemia (≥140)
Categorical model (4 level)
<110
110-139
141-199
>199
Restricted Cubic Spline
110
140
199
240

IR: incidence rate per 100 person-years, HR: hazard ratio, aHR: adjusted HR, RBG: random blood glucose level, BMI: body mass
index, Ref: reference group
*adjusted for age, sex, CD4 counts, anemia and alcohol drinking status at registration and ART status during follow-up
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Table 3. Risk incident TB by joint exposure to hyperglycemia and low BMI among people living with HIV enrolled Integrated
HIV Care Program, 2011-2017, Myanmar

Total

Incident TB

n

n

≥18.5

12,387

(<140)

<18.5 (Low)

Hyperglycemia
(≥140)

RBG (mg/dl)

BMI (kg/m2)

Euglycemia

IR [95% CI]

IR difference

HR [95% CI]

aHR* [95% CI]

1613

4.6 [4.4,4.9]

Ref

Ref

Ref

7,154

1748

10.9 [10.4, 11.4]

6.3 [5.7, 6.8]

2.06 [1.92, 2.20]

1.39 [1.30, 1.49]

≥18.5

868

114

5.2 [4.4, 6.3]

0.6 [-0.4, 1.6]

1.04 [0.86, 1.25]

1.03 [0.85,1.24]

<18.5 (Low)

456

153

21.0 [18, 24.7]

16.4 [13.1, 19.8]

3.09 [2.62, 3.64]

1.84 [1.55, 2.18]

RBG: random blood glucose level, BMI: body mass index, IR: incidence rate per 100 person-years, HR: hazard ratio, aHR: adjusted
HR, Ref: reference group
*adjusted for age, sex, CD4 counts, anemia and alcohol drinking status at registration and ART status during follow-up
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Figure 1. Estimated cumulative hazard of active TB during follow-up stratified by body
mass index among people living with HIV enrolled in Integrated HIV Care Program, 20112017, Myanmar
(a) Patients with euglycemia (RBG <140 mg/dl)

BMI: body mass index (kg/m2)
(b) Patients with hyperglycemia (RBG ≥140 mg/dl)

BMI: body mass index (kg/m2)
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Supplemental Table 1. Enrollment characteristics of people living with HIV included and
excluded in the study
Total
No.
41,179

Included
Row %
No.
20,865

Excluded
Row %
No.
50.7
20,314

Row %
49.3

Age (year)
<25
25-45
>45

3,132
31,252
6,795

7.6
75.9
16.5

1,690
15,873
3,302

8.1
76.1
15.8

1,442
15,379
3,493

7.1
75.7
17.2

Male
Female

23,896
17,283

58.0
42.0

11,538
9,327

55.3
44.7

12,358
7,956

60.8
39.2

Never
Habitual (daily)
Social (weekly)
Not recorded
CD4 cell count (cells/mm3)
>350
200-349
<200
Not recorded
WHO clinical staging
stage 1 or 2
stage 3 or 4
Not recorded
Previous ART before enrolled
No
Yes
Anemia
No
Mild or Moderate
Severe
Not recorded
Hepatitis B surface antigen
Negative
Positive
Not recorded
Hepatitis C antibody
Negative
Positive
Not recorded

26,183
3,709
9,568
1,719

63.6
9.0
23.2
4.2

13,856
1,582
5,001
426

66.4
7.6
24.0
2.0

12,327
2,127
4,567
1,293

60.7
10.5
22.5
6.4

7,535
8,302
20,588
4,754

18.3
20.2
50.0
11.5

4,627
5,083
10,977
178

22.2
24.4
52.6
0.9

2,908
3,219
9,611
4,576

14.3
15.8
47.3
22.5

17,590
22,672
917

42.7
55.1
2.2

11,419
9,446
0

54.7
45.3
0.0

6,171
13,226
917

30.4
65.1
4.5

24,182
3,483

87.4
12.6

12,515
1,481

89.4
10.6

11,667
2,002

85.4
14.6

11,812
21,084
3,200
5,083

28.7
51.2
7.8
12.3

7,722
11,511
1,348
284

37.0
55.2
6.5
1.4

4,090
9,573
1,852
4,799

20.1
47.1
9.1
23.6

31,889
2,995
6,295

77.4
7.3
15.3

17,380
1,672
1,813

83.3
8.0
8.7

14,509
1,323
4,482

71.4
6.5
22.1

31,281
3,542
6,356

76.0
8.6
15.4

16,898
2,142
1,825

81.0
10.3
8.7

14,383
1,400
4,531

70.8
6.9
22.3

Sex

Alcohol drinking
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RBG, mg/dl
Euglycemia (<140)
Hyperglycemia (≥140)
Not recorded
BMI (kg/m2)
<18.5
18.5-22.9
23-27.5
>27.5
Not recorded

27,820
1,944
11,415

67.6
4.7
27.7

19,541
1,324
0

93.7
6.3
0.0

8,279
620
11,415

40.8
3.1
56.2

13,135
13,251
4,526
2,366
7,901

31.9
32.2
11.0
5.7
19.2

7,610
8,669
3,028
1,558
0

36.5
41.5
14.5
7.5
0.0

5,525
4,582
1,498
808
7,901

27.2
22.6
7.4
4.0
38.9
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Supplemental Table 2. Baseline characteristics of people living with HIV enrolled Integrated HIV Care Program, 2011-2017,
Myanmar stratified by body mass index

No.

Underweight
<18.5 kg/m2
No.
Row %

BMI category
Normal
Overweight
18.5-22.9 kg/m2
23-27.5 kg/m2
No.
Row % No.
Row %

Obese
>27.5 kg/m2
No.
Row %

20,865
1,690
15,873
3,302
11,538
9,327
13,856
1,582
5,001
426

7,610
626
5,698
1,286
4,526
3,084
5,013
708
1,743
146

36.5
37
35.9
38.9
39.2
33.1
36.2
44.8
34.9
34.3

8,669
728
6,699
1,242
5,116
3,553
5,488
654
2,339
188

41.5
43.1
42.2
37.6
44.3
38.1
39.6
41.3
46.8
44.1

3,028
212
2,331
485
1,441
1,587
2,103
169
694
62

14.5
12.5
14.7
14.7
12.5
17
15.2
10.7
13.9
14.6

1,558
124
1,145
289
455
1,103
1,252
51
225
30

7.5
7.3
7.2
8.8
3.9
11.8
9
3.2
4.5
7

4,627
5,083
10,977
178
11,419
9,446
7,722
11,511
1,348
284

989
1,326
5,200
95
2,840
4,770
1,671
4,978
845
116

21.4
26.1
47.4
53.4
24.9
50.5
21.6
43.2
62.7
40.8

2,086
2,384
4,141
58
5,349
3,320
3,687
4,497
371
114

45.1
46.9
37.7
32.6
46.8
35.1
47.7
39.1
27.5
40.1

956
899
1,157
16
2,148
880
1,603
1,297
87
41

20.7
17.7
10.5
9
18.8
9.3
20.8
11.3
6.5
14.4

596
474
479
9
1,082
476
761
739
45
13

12.9
9.3
4.4
5.1
9.5
5
9.9
6.4
3.3
4.6

17,380
1,672

6,157
592

35.4
35.4

7,224
743

41.6
44.4

2,625
228

15.1
13.6

1,374
109

7.9
6.5

Total

Age (year)

Sex
Alcohol drinking

CD4 cell count
(cells/mm3)

WHO clinical staging
Anemia

Hepatitis B surface
antigen

Total
<25
25-45
>45
Male
Female
Never
Habitual (daily)
Social (weekly)
Not recorded
>350
200-349
<200
Not recorded
stage 1 or 2
stage 3 or 4
No
Mild or Moderate
Severe
Not recorded
Negative
Positive
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Hepatitis C antibody

Not recorded
Negative
Positive
Not recorded

RBG, mg/dl (Median, IQR)
RBG, mg/dl (2
categories)

RBG, mg/dl (4
categories)

Prior exposure to ART

Euglycemia
(<140)
Hyperglycemia
(≥140)
<110
110-140
141-199
>199
No
Yes

1,813
16,898
2,142
1,825
88.2 (75.6 –
106.2)

861
6,124
619
867

19,541

7,154

1,324
16,493
3,057
1,141
174
19,891
974

47.5
36.2
28.9
47.5

702
38.7
6,851
40.5
1,112
51.9
706
38.7
88.2 (75.6 –
106.2)

175
2,519
333
176

88.9 (75.6 – 108.0)

87 (75.0 – 103.0)

36.6

8,161

41.8

2,787

14.3

1,439

7.4

456

34.4

508

38.4

241

18.2

119

9

6,043
1,113
400
54
7,355
255

36.6
36.4
35.1
31
37
26.2

6,868
1,295
450
56
8,215
454

41.6
42.4
39.4
32.2
41.3
46.6

2,335
453
202
38
2,831
197

14.2
14.8
17.7
21.8
14.2
20.2

1,247
196
89
26
1,490
68

7.6
6.4
7.8
14.9
7.5
7

88.2 (75.0 – 106.2)

9.7
14.9
15.5
9.6

75
1,404
78
76

BMI: body mass index; ART: antiretroviral therapy; RBG: random blood glucose
Chi-square test for all categorical variables and Kruskal-Wallis rank sum test for all continuous variables resulted P value <0.05
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4.1
8.3
3.6
4.2

Supplemental Table 2. Interaction between low body mass index and hyperglycemia with the risk of active TB among people
living with HIV enrolled Integrated HIV Care Program, 2011-2017, Myanmar after excluding patients with TB disease
diagnosed with three months of enrollment (n=17,967)

Total

Random blood
glucose (mg/dl)

BMI (kg/m2)

Normoglycemia

Incident TB
IR [95% CI]

IR difference

HR [95% CI]

aHR [95% CI]

n

n

≥18.5

11,156

382

1.1 [1.0, 1.2]

Ref

Ref

Ref

(RBG ≤140)

<18.5 (Low)

5,711

305

1.9 [1.7, 2.1]

0.8 [0.5, 1.0]

1.78 [1.52,.2.05]

1.35 [1.16, 1.58]

Hyperglycemia

≥18.5

771

17

0.8 [0.5, 1.3]

-0.3 [-0.7, 0.1]

0.69 [0.43, 1.14]

0.72 [ 0.44, 1.17]

(RBG >140)

<18.5 (Low)

329

26

3.6 [2.5, 5.28]

2.5 [1.1, 4.9]

3.11 [2.09, 4.62]

2.23 [1.49, 3.33]

RBG: random blood glucose level, BMI: body mass index, IR: incidence rate per 100 person-years, HR: hazard ratio, aHR: adjusted
HR, Ref: reference group
*adjusted for age, sex, CD4 counts, anemia and alcohol drinking status at registration and ART status during follow-up
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Supplemental Figure 1. Flow diagram of the people living with HIV enrolled under
Integrated HIV Care program in Myanmar 2011-2017

Patients enrolled
2011-2017
41,179

Excluded (n=20,314)
RBG, weight, height not recorded
(n=15,406)
Received prior TB treatment
(n=6,669)
Received IPT (n=703)
Received treatment for MDR-TB
(n=36)

Included in study
20,865

Incident TB
3,628 (17%)

Incident TB
17,237 (83%)

RBG: random blood glucose, IPT: isoniazid preventive therapy, TB: tuberculosis, MDR-TB:
multidrug resistant TB
Supplemental Figure 2.a. Estimated hazard ratio of active TB across body mass index
among people living with HIV enrolled Integrated HIV Care Program, 2011-2017,
Myanmar using restricted cubic spline regression*
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* using 4 knots at equally spaced percentiles with a reference point at 18.5 kg/m2

Supplemental Figure 2.b. Estimated hazard ratio of active TB across random blood glucose
level among people living with HIV enrolled Integrated HIV Care Program, 2011-2017,
Myanmar using restricted cubic spline regression*

* using 4 knots at equally spaced percentiles with a reference point at 110mg/dl
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Supplemental Figure 3. Estimated cumulative hazard of active TB during follow-up
stratified by body mass index among people living with HIV enrolled in Integrated HIV
Care Program, 2011-2017, Myanmar after excluding patients with TB disease diagnosed
with three months of enrollment (n=17,967)
(a) Patients with euglycemia (RBG <140 mg/dl)

bmicat: body mass index category (kg/m2)
(b) Patients with hyperglycemia

bmicat: body mass index category (kg/m2)
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ABSTRACT
Background
Active TB is a known risk factor for all-cause mortality and unfavorable immunological and
virological responses in people living with HIV (PLHIV). Hyperglycemia is also associated with
risk of active TB disease and all-cause mortality. Among PLHIV, we estimated i) the association
between active TB with one-year all-cause mortality, and CD4 recovery and ii) whether glycemic
level mediates the association between active TB and all-cause mortality.
Methods
Antiretroviral therapy (ART) naïve PLHIV aged ≥15 years entering care (enrollment) between
2011 and 2018 in an outpatient HIV clinic, Taunggyi city, Myanmar were eligible. Active TB was
defined if PLHIV was on TB treatment at enrollment or started TB treatment within 90 days of
enrollment. Glycemic level was determined by random blood glucose (RBG) measured by
glucometer using capillary blood at enrollment to HIV care. We used a log binomial models to
estimate the association between active TB on mortality and a general linear mixed model to
estimate the association between active TB with change in CD4 count. We conducted a mediation
analysis using a product method to estimate direct, indirect and total effects of active TB on
mortality through glycemic levels.
Results
Of 2,035 PLHIV entered to care, 1,871 were included in the analysis. Among them, 687 (37%)
had CD4 count <100 cell/mm3 and 394 (21%) had active TB. The median RBG level was 86 mg/dl
(interquartile range: 74, 99). During one-year follow-up, 21% of the PLHIV in the cohort died and
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the mortality was significantly higher in PLHIV with active TB [adjusted relative risk:1.75, 95%
CI:1.38, 2.21]. The mean log CD4 count during the follow-up was significantly lower in PLHIV
with active TB compared to those without active TB [βTB = -0.61, 95% CI: -0.71, -0.51, βTB*followup month=

0.04, 95% CI: 0.03, 0.05], however, there was an upward trajectory of CD4 count after

ART in both groups. We did not observe glycemic status to be a key mediator in the relationship
between active TB and all-cause mortality.
Conclusion
One in five PLHIV had active TB in this cohort and the risk of mortality was higher in PLHIV
with active TB compared to those without active TB. Scaling up of TB preventive intervention in
this PLHIV cohort should be considered to reduce mortality among PLHIV.
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INTRODUCTION
Globally, one million out of 38 million people living with HIV (PLHIV) died in 2018 [3].
Tuberculosis (TB) is the principal comorbidity and leading cause of death accounting for 251,000
HIV-related deaths(range: 223,000-281,000)

[146]. Due to host-pathogen interactions, the

mortality risk of PLHIV with TB is two to four-fold higher compared to those who have HIV
infection alone [26,33]. One of the mechanisms of increased mortality due to TB is that HIV
depletes CD4 cells which are essential for autophagic clearance of TB bacteria leading to an
increase in bacterial load and severe TB disease in PLHIV [19,27]. In addition, during host immune
response to active TB, there is an increased T cells accumulation, rapid HIV replication in T cells
and direct T cells to cells HIV spread which are associated with higher HIV viral load and rapid
HIV disease progression [174]. Studies from African countries showed that PLHIV with TB
treatment at ART initiation had lower CD4 cell counts at baseline but greater increases in CD4+T
cell during follow-up [175–177]. However, there is a dearth of knowledge from high HIV/TB
burden countries in Asia on the impact of active TB on CD4 T+ cells after the start of antiretroviral
therapy (ART) [178].
Most HIV/TB coinfection and associated mortality occurred in resource limited settings in
early ART era before 2010. During that time, ART availability was limited and PLHIV were
initiated on ART in late disease stage which increased the risk of TB related mortality due to
depleted CD4 cells [28]. With increased ART coverage during the last decade in many high
HIV/TB burden countries, it is important to assess other factors that might contribute to increased
risk of mortality associated with TB disease.
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Hyperglycemia, the main clinical feature of type 2 diabetes mellitus, is an emerging
comorbidity in PLHIV, and occurs as a result of adverse events of commonly used ART and/or
the increased risk of metabolic disease amongst an aging PLHIV population [58–61,64]. Previous
studies have suggested that hyperglycemia in PLHIV is associated with an increased risk of death
and adverse outcomes due to worsening diabetes, HIV or ART related complications [68–70,145].
On the other hand, emerging evidence suggests that TB disease increases the risk of stress
hyperglycemia, a state of transient hyperglycemia induced by the acute illness of TB disease
[103,104]. Although there is no evidence yet in the context of HIV, stress hyperglycemia in other
critical illnesses is associated with adverse clinical outcomes and increased mortality [179–182].
Hence, it is plausible that the increased risk of TB-related mortality in PLHIV may be mediated
by hyperglycemia. Among PLHIV, improved understanding of the role of hyperglycemia in TB
related mortality may inform therapeutic efforts to optimize glycemic control and thereby reduce
mortality in HIV/TB patients. There are reviews and guidelines currently used to address the
control of the hyperglycemia in TB patients [183,184]. More evidence, however, is needed to
better formulate clinical guidelines for the management of TB and hyperglycemia in PLHIV to
reduce adverse TB and HIV outcomes. In this study, we estimated the association between active
TB with all-cause mortality, change in CD4 cells and virological failure after one year on ART.
We also assessed whether blood glucose level mediates the association between active TB and allcause mortality among PLHIV.
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METHODS
Study population
Adult PLHIV >15 years old enrolled between 2011 and 2018 in an outpatient HIV clinic
in Taunggyi city, Myanmar, who were antiretroviral therapy (ART) naïve, had TB treatment
information and random blood glucose (RBG) measurements at enrollment were eligible. Pregnant
women, PLHIV without RBG measurements, drug resistant TB cases and those taking isoniazid
preventive therapy were excluded from the study.
Study Setting
Myanmar is one of the 30 high dual HIV/TB burden countries in the world. The study site
for this study was a HIV clinic operated under the Integrated HIV Care Program jointly operated
by the National HIV/AIDS program and the International Union Against Tuberculosis and Lung
Disease. Standard of care for PLHIV entered the HIV care included RBG, CD4, weight and height
measurements, TB disease screening, treatment and prophylaxis for opportunistic infections
according to WHO and National HIV treatment guidelines [185,186]. TB disease screening was
also done during monthly or quarterly follow-up visits. Active TB diagnosis is based on TB
symptoms, acid-fast bacilli (AFB) sputum smears, sputum specimens for Xpert MTB/RIF assays
and/or chest X-ray. Clinical details were recorded in individual medical record files by medical
officers at each patient visit.
Measures and data sources
The primary exposure of interest was prevalent TB disease. PLHIV who were on TB
treatment at study enrollment or started TB treatment within 90 days of enrollment were defined
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as having prevalent TB disease. PLHIV without a record of TB treatment were classified as not
having prevalent TB disease. All forms of TB disease (bacteriologically confirmed, radiologically
diagnosed, pulmonary or extra-pulmonary TB disease) were included.
The primary outcome variable was all-cause mortality during one year of follow-up. Allcause mortality was determined using patient medical records. The secondary outcomes included
CD4 cell count change and virological failure. In this setting, CD4 cells were measured at
enrollment or at the time of starting ART and every 3 to 6 months thereafter using automated flow
cytometry (CyFlow® Counter 2, Partec GmbH, Germany) in the public health laboratory. The
CD4 cell count was determined using all CD4 measurements from baseline to 15 months of ART
as some of the patients received their 12th months of blood investigation a few months later.
Routine viral load testing was performed at 6 or 12 months after the start of ART to monitor
virological suppression (this has been the practice since 2017). Viral load testing was carried out
using real time PCR (RT-PCR) (GENERIC HIV Viral Load, Biocentric, Bandol, France) which
has a lower limit of detection of 250 copies/ml. For the virological failure outcome at one year, we
included any viral load result performed between 9 and 15 months after the start of ART. PLHIV
with two viral load measurements >1000 copies/ml were considered to have a virological failure.
The mediator variable of interest was the continuous measure of RBG level measured by
glucometer using capillary blood at enrollment to HIV care. Other covariates included age, sex,
body mass index (BMI), hepatitis B and C status and ART status at enrollment. Patients were
considered hepatitis B positive if they had positive HBs antigen test and hepatitis C positive if they
had positive HCV antibodies. BMI was calculated from a patient’s weight and height (weight in
kg / (height in metre)2) measured at enrollment.
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All data were extracted from patients’ electronic medical records, which were digitized
from a hard copy of the patients’ medical record.
Ethics
The study was approved by Institutional Review Board at Georgia State University, the
Union Ethics Advisory Group (Paris, France) and Ethics Review Committee at the Department of
Medical Research, Ministry of Health and Sports, Myanmar. A waiver of informed consent was
granted by ethics review bodies, as the study collected and analyzed de-identified routine recording
and reporting data.
Statistical analysis
The analytic goals were to 1) estimate the association of active TB on all-cause mortality,
the change in CD4 count, and HIV viral load and 2) determine the mediating role of RBG in the
relationship between active TB and all-cause mortality. Patients’ characteristics were compared
between those with and without active TB using the chi-square test for categorical variables and
the Wilcoxon rank-sum test for continuous measures. We used log binomial models to estimate
risk ratios and 95% confidence intervals for the relationship between active TB on one-year allcause mortality. A general linear mixed model with random intercept was used to estimate the
association of active TB with CD4 count change during one year of ART. All final regression
models were adjusted for potential confounders identified by unadjusted analyses and directed
acyclic graph theory [187]. For mediation analysis, we used the product method [188] based on
the assumed causal pathway presented in Figure 1. We estimated bias-corrected bootstrap
confidence intervals (CIs) with 1000 repetition for indirect effect, direct effect, and total effects.
The model fit was tested using F-test and R2 for linear regression, AIC and scaled deviance and
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Pearson Chi-square test for log binomial model, and F-test and AIC for general linear mixed
model. The level of significance was set at 0.05.

RESULTS
Study population
Of 2,035 PLHIV enrolled at the study site between 2011 and 2018, pregnant women
(n=67), PLHIV who had not had RBG measurements (n=89), those who were taking isoniazid
preventive therapy (n=8) and initiated TB treatment two months before enrollment were excluded
from the study (Figure 1). Of 1,871 PLHIV included in the analysis, 1,598 PLHIV initiated on
ART and 1,571 had baseline CD4 measurements. At enrollment, the median RBG level of the
study cohort was 86 mg/dl [IQR: 74, 99], 691 (37%) patients had BMI <18.5 kg/m2 and 687 (37%)
had CD4 cell counts <100 cell/ mm3 (Table 1).
Overall, the prevalence of active TB was 21%. The median RBG among PLHIV with no
TB disease was 87 mg/dl [interquartile range (IQR): 74, 101] and among those with TB disease
was 85 mg/dl [IQR:72,95]. The prevalence of active TB was different across patients’ sex, age,
BMI, CD4 cell count, WHO clinical staging, anemia and ART status at enrollment (Table 1).
Association between prevalent active TB on all-cause mortality, change in CD4 count, and
virological response
We compared all-cause mortality among PLHIV with and without active TB. The
proportion of PLHIV who died from any cause during one year of follow-up among patients with
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active TB was higher than among those without active TB (20% vs 13%) (Table 2). The
unadjusted risk of all-cause mortality among PLHIV with active TB was 1.55 (95% CI: 1.21, 1.97)
times the risk in those without active TB. After controlling for age, sex, duration on ART and
glycemic level, the adjusted relative risk was 1.75 (95%CI: 1.38, 2.21) and when CD4 count, BMI
and anemia status were included in the adjusted model, the relative risk was 1.01 (95% CI: 0.80,
1.27) (Table 2).
The median baseline CD4+T cell count was 135 cell/mm3 [IQR: 52, 271]. The CD4+T cell
results after one year of ART were available in 549 patients and the median was 284 cell/mm3
[IQR: 189,478]. We fitted a linear mixed model using the log transformation of CD4 +T cell count
to estimate the change of CD4 counts during one-year follow-up on ART as a function of active
TB and follow-up time. The interaction term between active TB status and time was included in
the model. There was an upward trend of changes in CD4 cell counts after ART and the trend was
significant irrespective of the patient’s active TB status (Figure 3). However, a patient with active
TB had a significantly lower mean CD4 cell count compared to those without active TB [βTB = 0.61, 95% CI: -0.71, -0.51, βTB*follow-up month= 0.04, 95% CI: 0.03, 0.05] (Supplemental Table 1).
Among PLHIV initiated on ART, 182 (10%) were tested for viral load between 9 and 15
months after starting ART. Among those tested, 37 (20%) had detectable viral load. A lower
proportion of PLHIV with active TB were tested for viral load (8% vs 12%) and a higher
proportion had detectable viral load (25% vs 20%) (Table 3). As only 50% of PLHIV with
detectable viral load were tested for viral load again, we cannot make any meaningful assessment
of association between active TB and one-year virological failure.
Mediating effect of blood glucose level on association between active TB and mortality
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The adjusted estimated coefficients of the regression models of mediation analyses are
presented in Figure 2. In model 1, we included age and sex as potential confounders and in model
2, age, sex, CD4 cells and BMI as potential confounders. Active TB was associated with a lower
glycemic level. The average RBG level in PLHIV with active TB disease was 0.29 mg/dl lower
than in those without active TB after adjusting for age, sex (result from model 1). The direct effect,
indirect effect and total effect of active TB on mortality are presented in Table 4. From the adjusted
model 1, the direct effect or the relative risk of mortality in patients with active TB was 1.546
times compared to those without active TB after controlling for mediator [95% CI: 1.207, 1.991].
However, the indirect effect of active TB on mortality through glycemia was 0.986 [95% CI: 0.962,
0.999]. We did not calculate the proportion mediated as the direct and indirect effect are not in the
same direction.

DISCUSSION
The prevalence of TB disease in this PLHIV cohort is very high as one in five PLHIV had
TB disease. Overall mortality was high with 14% of the cohort died during one year of follow-up.
PLHIV with active TB had 70% higher one-year all-cause mortality compared to those without
active TB. Our study showed that CD4 cell count of PLHIV with active TB increased after ART.
Despite this, PLHIV with active TB had a lower CD4 cell count than those without active TB after
one year on ART. A finding that was contrary to our hypothesis and the current literature was that
active TB disease was associated with lower glycemic levels.
Similar to the findings from African studies, we observed an association between active
TB and one-year all-cause mortality in this HIV cohort [28–30]. The association was closed to null
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after adjusting for CD4 count, BMI and anemia. However, we believed that CD4 count, BMI and
anemia are mediators variables between active TB and mortality or they are ancestor or cause of
the TB disease in causal pathway [187] which are not needed to adjust as they are not confounders.
The CD4 count of PLHIV with active TB in this cohort increased one year after ART
initiation. This finding was similar to the finding from the systematic review that compared the
CD4 response in patients with TB and without TB showed that both groups have the similar CD4
response after ART initiation [178]. However, there are some studies from Africa which showed
that HIV/TB coinfected patients are less likely to experience CD4 cell recovery after ART [189–
191]. The different in the finding may be due to the difference in defining CD4 cell recovery and
not accounting for correlation of CD4 cell count within individual in estimating the CD4 cell
response in those studies. As there are very few studies from Asia assessing the impact of active
TB on immunological responses using longitudinal CD4 count data, our study results can shed
light on the effective immune response among PLHIV with active TB who received ART and antiTB treatment.
In this cohort, higher proportion of patients with active TB had a viral load >1000
copies/ml after one year on ART compared to those without active TB (25% vs 16%) but the
differences were not statistically significant. We cannot assess the association between active TB
and virological failure because in this cohort because only a small proportion of patients (11%)
were tested for viral load at one year of starting ART and 15 out of 31 patients with viral load
>1000 copies/ml repeated the viral load testing.
Our mediation analysis suggested that the association between active TB and risk of
mortality was mediated through glycemic levels, but the direct and indirect effect are in opposite
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direction. As a result, the total effect of active TB on risk of mortality was attenuated when blood
glucose level was included in the model (direct effect=0.45 and total effect = 0.43). As the risk of
TB associated with hyperglycemia is poorly understood, the effect we observed in this study can
be plausible mechanism in HIV population or can be by chance. Hence, more research is needed
to study the role of glycemia in TB related mortality using fasting blood glucose or HbA1c to
inform the management of hyperglycemia and TB comorbidities in HIV population.
This study was subject to limitations. Glycemic level was measured using measurements
of RBG which may not reflect underlying glucose control or dysglycemia (hyperglycemia or
hypoglycemia). The misclassification of glucose control may bias our results toward or away from
the null. We defined prevalent TB using a TB treatment record. There could have been patients
who were diagnosed with TB disease but had yet to start TB treatment. However, as far as we
know, all the patients diagnosed with active TB were treated unless they died or were lost to follow
up before treatment could be started. Not all patients were viral load tested at 6 or 12 months of
the start of ART which limited the ability to assess the association between active TB and
virological failure. In the adjusted model, we only adjusted for potential confounders using the
baseline patient characteristics and some covariates may have time-varying effects on outcome. In
addition, there will be other unmeasured confounders such as smoking and other metabolic profiles
that can impact on the association between glycemic level and mortality and bias our estimates.
As the study population was from one HIV clinics and about 8% of the patients were excluded
from the study, our results may not be generalizable to all PLHIV in Myanmar.
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CONCLUSIONS
Despite these limitations, our study showed that PLHIV with active TB expereince higher
mortality and lower mean CD4 cell counts during the follow-up compared to those who did not
have TB, however, they achieved good immune recovery once on ART, and TB treatment. We did
not observe the relationship between active TB and virological failure and the glycemic status as
a mediator in the relationship between active TB and all-cause mortality. Future studies using
HbA1c or fasting blood glucose should be conducted to understand the role of hyperglycemia in
increasing the risk of mortality in HIV/TB coinfected patients.
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Table 1. Demographic and clinical characteristics of PLHIV with and without active TB who
enrolled in Integrated HIV Care Program Clinic in Taunggyi City, Myanmar, 2011-2018

Age in year

15-24
25-45
≥46
Sex
Female
Male
Random blood glucose mg/dl*
BMI kg/m2
<18.5
18.5-22.9
23-27.5
>27.5
Unknown
Alcohol drinking
Never
Habitual
Social
Unknown
3
CD4 count cell/mm
CD4count
category
>350 cell/mm3
201-350 cell/mm3
100-200 cell/mm3
<100 cell/mm3
Unknown
WHO staging
1 and 2
3 and 4
not recorded
Anemia
No anemia
Mild to Moderate
Severe
Not recorded
a
Hepatitis B
Negative
Positive
Unknown
b
Hepatitis C
Negative
Positive
Unknown

Total
n
1871
102
1,408
361
774
1,097
86 (74, 99)
691
688
221
40
231
1,333
172
326
40
150 (54, 325)
383
338
323
688
139
888
979
4
681
934
142
114
878
61
932
856
83
932

No active TB
n
%
1479
79
89
87.3
1,097
77.9
293
81.2
637
82.3
842
76.8
87 (74, 101)
463
67
586
85.2
206
93.2
37
92.5
187
81
1,038
77.9
142
82.6
262
80.4
37
92.5
190 (67, 340)
363
302
252
447
115
861
614
4
631
671
80
97
724
49
706
704
69
706

PLHIV: people living with HIV, BMI: body mass index
a
Tested using hepatitis B surface antigen (Alere Determine™)
b
Tested using HCV antibody test (OraQuick® immunoassay).
66

94.8
89.3
78
65
82.7
97
62.7
100
92.7
71.8
56.3
85.1
82.5
80.3
75.8
82.2
83.1
75.8

Active TB
%
n
392
21
13
12.7
311
22.1
68
18.8
137
17.7
255
23.2
85 (72,95)
228
33
102
14.8
15
6.8
3
7.5
44
19
295
22.1
30
17.4
64
19.6
3
7.5
67 (30, 135)
20
36
71
241
24
27
365
0
50
263
62
17
154
12
226
152
14
226

5.2
10.7
22
35
17.3
3
37.3
0
7.3
28.2
43.7
14.9
17.5
19.7
24.2
17.8
16.9
24.2

Table 2. All-cause mortality among PLHIV during one year of follow-up according to active TB status

Active TB

Alive

Died

Model 1

Model 2

Model 3

Total

n (%)

n (%)

RR [95% CI]

RR [95% CI]

RR [95% CI]

1,871

1606 (86)

265 (14)

No

1,479

1291 (87)

188 (13)

Ref

Ref

Ref

Yes

392

315 (80)

77 (20)

1.55 [1.21,1.97]

1.75 [1.38, 2.21]

1.01 [0.80,1.27]

RR: risk ratio, PLHIV: people living with HIV, Ref: reference group, Bold indicates 95% confidence interval estimate did not include
null value
Model 1: crude RR
Model 2: adjusted for age, sex, duration on ART and blood glucose level
Model 3: adjusted for age, sex, CD4, body mass index, anemia status, duration on ART and blood glucose level

Table 3. HIV viral load testing results after one year of ART among PLHIV with or without active TB enrolled to HIV care between
2011 and 2018 in outpatient HIV clinic in Taunggyi city, Myanmar (n=1598)

Total patients initiated on ART
Viral load tested at one-year of ART
Viral load detectable
Viral load >1000 copies/ml
Viral load testing repeated
Virological failure

Without active TB
n (%)
1256
154 (12%)
30 (20%)
24 (16%)
11 (46%)
6 (55%)

With active TB
n (%)
342
28 (8%)
7 (25%)
7 (25%)
4 (57%)
1 (25%)

PLHIV: people living with HIV
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Table 4. Estimated direct effect of active TB on all-cause mortality, indirect effect of active TB on mortality through glycemic level
and total effect of active TB on all-cause mortality among PLHIV enrolled to HIV care between 2011 and 2018 in outpatient HIV
clinic in Taunggyi city, Myanmar
Unadjusted

Adjusted Model 1

Adjusted Model 2

Coefficient

RR [95% CI]

Coefficient

RR [95% CI]

Coefficient

RR [95% CI]

Controlled direct effect

.455

1.576 [1.230, 2.015]

.436

1.546 [1.207, 1.991]

0.046

1.047 [0.815,1.351]

Natural indirect effect

-.017

0.983 [0.958,0.998]

-.014

0.986 [0.962, 0.999]

-0.004

0.996 [0.975,1.003]

Total effect

.438

1.550 [1.215,1.985]

.422

1.524 [1.184, 1.956]

0.042

1.043 [0.809, 1.341]

Model 1: Adjusted for age, sex
Model 2: Adjusted for age, sex, CD4 cell count and body mass index
Bold indicates 95% confidence interval estimate did not include null value
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Figure 1. Flow diagram of the people living with HIV enrolled under Integrated HIV Care
program in Myanmar 2011-2018

PLHIV entered to HIV care
2011- 2018
2,035

Excluded n=164
Pregnant women n=67
No RBG record n=89

Included in mortality
analysis
1,871

Started ART
1,598

TB disease

No TB disease

392 (21%)

1,479 (79%)

Died
77 (20%)

Missing CD4 record
n=27
Included in CD4 trend
analysis
1,571

Died
188 (13%)

TB disease

No TB disease

340 (21%)

1,238 (79%)

TB: tuberculosis, PLHIV: people living with HIV
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Figure 2. Directed acyclic graph (DAG) depicting the assumed causal structure for all-cause
mortality among people living with HIV due to active TB.

Model 1

Active
TB (Yes)

Confounders:
Age, sex

θ2= .049*

β1= -.293*

All-cause mortality

Glycemic level

θ1= .436*
Model 2

Confounders:
Age, sex,
CD4, BMI

Active
TB (Yes)

θ2= .039

β1= -.110
Glycemic level

All-cause mortality

θ1= .046

Log binomial regression form:
log[𝑝ሺ𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 = 1ȁ 𝑇𝐵, 𝐺𝑙𝑦𝑐𝑒𝑚𝑖𝑐, 𝐶𝑜𝑛𝑓𝑜𝑢𝑛𝑑𝑒𝑟𝑠)] = 𝜃0 + 𝜃1 𝑇𝐵 + 𝜃2 𝐺𝑙𝑦𝑐𝑒𝑚𝑖𝑐 + 𝜃3 𝐶𝑜𝑛𝑓𝑜𝑢𝑛𝑑𝑒𝑟𝑠
Linear regression form:
E[𝐺𝑙𝑦𝑐𝑒𝑚𝑖𝑐ȁ 𝑇𝐵, 𝐶𝑜𝑛𝑓𝑜𝑢𝑛𝑑𝑒𝑟𝑠] = 𝛽0 + 𝛽1 𝑇𝐵 + 𝛽2 𝐶𝑜𝑛𝑓𝑜𝑢𝑛𝑑𝑒𝑟𝑠

β1= regression coefficient for effect of active TB on glycemic level (mediator). θ2= regression
coefficient for mediator on all-cause mortality. θ1= regression coefficient for active TB on allcause mortality controlling for mediator [controlled direct effect]. β1* θ2= Natural indirect effect
*p-value <0.05
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Figure 3. Estimated CD4 cell count changes of people living with HIV with and without active
TB after antiretroviral therapy from the adjusted linear mixed model

CD4 cell counts were back transformed from log CD4

71

Supplemental table 1. Random intercept model fitting the change of log CD4 counts as a function of active TB disease and time on
ART among patients enrolled in the HIV program between 2011-2018 (number of observations=4,411, number of patients=1,561)
Model 1
Parameter

Characteristics

Estimate

Fixed Effects
Intercept
Active TB

4.97
No
Yes

Model 2

95% Confidence

p-value

Interval

Parameter
Estimate

Lower

Upper

4.92

5.02

<0.001

Ref

5.30

95% Confidence

p-value

Interval
Lower

Upper

5.12

5.46

<0.001

Ref

-0.61

-0.71

-0.51

<0.001

-0.61

-0.71

-0.51

<0.001

Follow up time (months)

0.07

0.06

0.07

<0.001

0.07

0.06

0.07

<0.001

Follow up time* active TB

0.04

0.03

0.05

<0.001

0.04

0.03

0.05

<0.001

-0.01

-0.01

-0.00

<0.001

-0.06

-0.14

0.02

0.143

0.43

0.52

Age (year)
Sex

Male
Female

Ref

Random Effects
Variance estimates
Intercept

0.48

0.44

0.53

0.47

Overall Model test
AIC

9738

9697

BIC

9776

9748

TB: tuberculosis, Ref: reference group, AIC: Akaike information criterion, BIC: Bayesian information criterion
Model 1: Adjusted for follow up time and included interaction term between follow up time and active TB
Model 2: Adjusted for follow up time, age and sex and included interaction term between follow up time and active TB
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1

ABSTRACT

2

Background: Hepatitis C virus (HCV) and hepatitis B virus (HBV) coinfection are associated

3

with increased mortality in people living with HIV (PLHIV). In addition, diabetes and

4

hyperglycemia are common in PLHIV. Using routinely collected clinical data from PLHIV from

5

Myanmar, we assessed whether associations between HBV/HCV coinfection and all-cause

6

mortality differed by hyperglycemia status.

7

Methods: Adult PLHIV (≥15 years) from Myanmar who initiated antiretroviral therapy between

8

May 2005 and June 2017 were eligible. HBV and HCV coinfection were measured by hepatitis B

9

surface antigen test and HCV antibody test, respectively, and hyperglycemia by random blood

10

glucose (≥140 mg/dl) at entry to HIV care. Cox proportional hazards models were used to compare

11

all-cause mortality rates in participants by HCV/HBV coinfection and hyperglycemia status.

12

Results: Among 27,722 PLHIV, 2,260 (8%) had HBV, 2,265 (9%) had HCV, 178 (0.6%) had

13

both HBV/HCV coinfection and 1425 (5%) had hyperglycemia. The overall mortality rate was 3.8

14

per-100 person-years. The mortality rate among PLHIV with HBV was 4.6, with HCV was 5.1

15

and with both HBV and HCV was 7.11 per 100-person-years. There was an association between

16

HBV and HCV coinfections and all-cause mortality, and the association between HCV coinfection

17

and all-cause mortality was greater in patients with hyperglycemia [adjusted hazard ratios: 1.58

18

(95% CI: 1.09, 2.30) for HCV and 3.21 (95% CI: 1.17, 8.84) for HBV/HCV coinfection compared

19

to HIV mono-infection].

20

Conclusion: Prevention, screening and treatment of chronic HBV and HCV are needed to scale

21

up in this population and clinical guideline to manage hyperglycemia should be developed to

22

reduce mortality.
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23

BACKGROUND

24

The global progress in reducing HIV-related mortalities is challenged by hepatitis B virus

25

(HBV) and hepatitis C virus (HCV) coinfection in people living with HIV (PLHIV). In 2015, the

26

estimated global prevalence of HBV was 7.4% and HCV was 6.2% among PLHIV [192,193].

27

Cirrhosis and liver cancer due to HBV and HCV are major causes of death globally. Among

28

PLHIV, coinfection with HBV or HCV is associated with increased risk of mortality due to

29

increased risk of chronic liver disease, accelerated liver fibrosis and cirrhosis, and complications

30

that occur in the management of both infections in PLHIV coinfected with HBV or HCV [40,42–

31

45].

32

Further, type 2 diabetes mellitus (T2DM) is an emerging comorbidity among PLHIV and

33

T2DM comorbidity in PLHIV is associated with increased risk of mortality [68–70]. In addition,

34

T2DM is associated with HCV although the direction and mechanism of the relationship is

35

unknown [122]. Extrahepatic effects of HCV viremia may disrupt endocrine function and glucose

36

homeostasis resulting in increased risk of insulin resistance, hyperglycemia and T2DM

37

[123,125,126]. Most importantly, comorbidities with HBV or HCV and T2DM together may

38

increase the risk of mortality in PLHIV. Preliminary studies suggest that insulin resistance,

39

hyperglycemia, and T2DM are associated with accelerated liver fibrosis, which is the leading cause

40

of liver-death in HBV or HCV coinfected patients [194,195]. However, few studies have examined

41

the risk of mortality associated with HBV and/or HCV in the context of hyperglycemia.

42

Managing HCV or HBV and hyperglycemia simultaneously is a common and major

43

challenge in many HIV clinical settings. Hence, developing clinical guidelines to manage

44

comorbidities among PLHIV are urgently needed. Given limited information on the relationship
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45

between HBV or HCV coinfection and mortality in the presence of hyperglycemia in PLHIV we

46

aimed to determine 1) the association between HBV and HCV coinfection with all-cause mortality

47

in PLHIV and 2) whether the association between HBV and HCV coinfection with all-cause

48

mortality in PLHIV varied by hyperglycemia status.

49

50

METHODS

51

Study Design

52

We conducted a retrospective cohort study using data that routinely collected between May

53

2005 and June 2017 in the Integrated HIV Care program in Myanmar.

54

Study setting and source of data

55

Myanmar with an estimated population of 52 million is located in the South-East Asia

56

Region. In 2018, 240,000 people were living with HIV in the country [3]. According to a 2015

57

prevalence survey, the prevalence of HBV was 6.5% and HCV was 2.7% in the general population

58

[196]. The Integrated HIV Care Program has been implemented jointly by National AIDS

59

Programme and International Union Against Tuberculosis and Lung Disease since 2005 and

60

providing treatment and care to PLHIV in 5 regions/states in Myanmar through 49 clinics. The

61

description of Integrated HIV Care Program was described elsewhere [162]. Briefly, at enrollment

62

to HIV care at the clinic, patients received clinical examination and baseline laboratory

63

investigations including HBV, HCV and tuberculosis (TB) disease screening, CD4 count,

64

hemoglobin and random blood glucose (RBG) measurement. Patients received antiretroviral

65

therapy (ART) and treatment for other opportunistic infections according to National and WHO
76

66

HIV clinical guidelines [186,197]. The TDF and lamivudine containing ART regimen which is

67

also active against HBV was widely available since 2011. The chronic HCV treatment using direct-

68

acting antivirals was not available during the study period [198]. Patients were followed up

69

routinely at every three months. Patient outcomes were recorded as regular follow-up (attending

70

clinic appointment regularly), death (patient’s family or the outreach workers reported to the clinic

71

that the patient had died), lost to follow-up (not attending the clinic within three months after the

72

scheduled appointment date) and transfer out (patient was transferred out to other HIV care

73

program). Date of death was recorded from hospital records if patients died at the hospital or as

74

reported by families if the patient died at home. At every visit, patients’ data were recorded on

75

paper-based patient medical records by medical officers and entered into an electronic database by

76

data entry operators. For this study, data of patients who initiated ART between 1st May 2005 and

77

31st June 2016 with their follow-up and outcome data until 31st June 2017 were extracted from the

78

electronic database.

79

Study participants

80

PLHIV aged ≥15 years who initiated ART between May 2005 and June 2016 and who

81

were tested for HBV and/or HCV coinfection at enrollment to HIV care were eligible. PLHIV

82

whose HBV and HCV status were not known were excluded.

83

Study variables

84

The primary exposure variables was HBV and/or HCV coinfection status which was

85

extracted from patients’ medical records. As standard of care, hepatitis screening is performed for

86

all patients at the time enrollment to HIV care. HBV infection status was measured using Hepatitis

87

B surface antigen (HBsAg) (Alere Determine™) and HCV infection measured by HCV antibody
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88

testing (OraQuick® immunoassay). HBV and/or HCV infection status was categorized as HIV

89

mono-infection if the patient was not tested positive for both HBV and HCV, HBV coinfection if

90

the patient was tested positive for HBV only, HCV coinfection if the patient was tested positive

91

for HCV only and both HBV and HCV coinfection if the patient was tested positive for both HBV

92

and HCV.

93

The primary outcome was all-cause mortality defined as death due to any cause between

94

the date of ART initiation and 30th June 2017 (the end of follow-up). All-cause mortality status

95

was determined from patients’ medical records.

96

Covariates included age, gender, alcohol drinking, body mass index (BMI), CD4 cell count,

97

WHO clinical staging, anemia and hyperglycemia at enrollment to HIV care and calendar year of

98

ART initiating. RBG ≥140 mg/dl was defined as hyperglycaemia according to previous studies

99

and WHO 2-hour postprandial blood glucose classification for diagnosis of prediabetes [164–166].

100

RBG was measured at enrolment by glucometer using capillary blood. Alcohol drinking status was

101

based on self-reported drinking habit at the time of enrollment. BMI was calculated from

102

enrollment weight and height. BMI and anemia were categorized according to WHO guidelines

103

for Asian populations [163,199]. Anemia was categorized based on hemoglobin (mg/dl) levels:

104

normal (male, ≥13 g/dl; female, ≥12 g/dl), mild (male, 11–12.9 g/dl; female, 11–11.9 g/dl),

105

moderate (both sexes, 8.0–10.9 g/dl) and severe anemia (both sexes <8.0 g/dl). Calendar year of

106

ART initiation was dichotomized into the period before (1st May 2005 to 31st December 2010) and

107

after (1st January 2011 to 30th June 2016) TDF was widely available.

108

Analysis and statistics
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109

Numbers and proportions were used to summarize the prevalence of HBV and HCV

110

coinfection and the characteristics of the study cohort. All-cause mortality rates (per 100 person-

111

years of follow-up) were calculated for four groups: HIV mono-infection, HBV coinfected, HCV

112

coinfected and HBV-HCV coinfected. Follow-up person-time was calculated from the date of

113

ART initiation to date of all-cause mortality, loss to follow-up, or end of follow-up period (30th

114

June 2017). We compared mortality rate differences in coinfected patients compared to the HIV

115

mono-infection group. Kaplan-Meier survival curves were plotted from time to ART initiation to

116

all-cause mortality stratified by HBV and/or HCV coinfection status. We used Cox proportional

117

hazard models to estimate hazard ratios (HR) with 95% confidence interval (CI) to determine the

118

association of HBV and/or HCV coinfection with all-cause mortality. Proportional hazard

119

assumptions were assessed using log-log plots and Schoenfeld residuals [200]. The variables for

120

which the proportional hazard assumption did not hold were included as a time varying covariate

121

in the model. Final models were adjusted for potential confounders based on directed acyclic graph

122

theory [201] and observed characteristics associated with exposure (HBV and/or HCV coinfection)

123

and outcome (all-cause mortality) in bivariate analysis. We stratified the Cox proportional hazard

124

models by hyperglycemia status to determine whether the association between HBV and HCV

125

coinfection with all-cause mortality in PLHIV varied by hyperglycemia status. Sensitivity analyses

126

were performed to account for bias due to 1) exposure misclassification by estimating relative risk

127

using different sensitivities and specificities of the measurement, 2) outcome misclassification by

128

fitting the Cox models after reclassified the patients who were loss to follow-up as deaths, and 3)

129

unknown confounders by calculating e-values [167,168]. All analysis was performed using

130

STATA version 14.2 (College Station, TX, USA).

131

Ethics approval
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132

The ethics approval was obtained from the Ethics Advisory Group of The Union, Paris,

133

France (EAG/53/17), the ethical review committee of the Department of Medical Research,

134

Ministry of Health and Sports, Myanmar (Ethics/DMR/2018/053) and Institutional Review Board

135

at Georgia State University (H18392). We also obtained permission to conduct the study from the

136

National AIDS Programme, Myanmar.

137

138

RESULTS

139

During the study period, 31,047 PLHIV initiated ART and 27713 (89%) patients tested for

140

HBV and 27,690 (89%) tested for HCV. Of 27,722 patients eligible for this study, 2260 (8%) were

141

HBV positive, 2265 (8%) were HCV positive and 178 (0.6%) were both HBV and HCV positive

142

(Figure 1). The median age was 35 years (interquartile range: 30-42), 57% of patients were male,

143

5% had hyperglycemia (RBG ≥140 mg/dl), 36% had BMI <18.5 kg/m2 and 59% had CD4 <200

144

cell/mm3) (Table 1).

145

Patient characteristics and the proportion of HBV, HCV or both HBV and HCV coinfection

146

are presented in Table 1. The prevalence of HCV coinfection was higher in patients older than 45

147

years compared to those in younger age groups (11% vs 8%), in male patients compare to female

148

(11% vs 5%), in patient with hyperglycemia compared to euglycemia (12% vs 8%) and in social

149

or habitual alcohol drinkers compared to those who never drunk (10% and 13% vs 6%).

150

Patient characteristics associated with all-cause mortality

151

A total of 27,722 patients contributed to 96,994 person-years was included in this analysis.

152

During the median follow-up of 3.1 years (IQR 1.5 – 5.1 years), 3655 (13%) patients died and the
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153

overall mortality rate was 3.8 (95% CI:3.7, 3.9) per 100 person-years (Table 2). Patients who were

154

older than 45 years [HR:1.98, 95% CI:1.67, 2.35], were male [HR: 1.83, 95% CI: 1.71, 1.97], had

155

hyperglycemia [HR: 1.33, 95% CI 1.17, 1.52], were habitual drinker [HR: 1.87, 95% CI: 1.69,

156

2.06], had BMI <18.5 [HR: 1.82, 95% CI: 1.68, 1.97], CD4 count <200 cell/mm [ HR: 33.24, 95%

157

CI:2.84, 3.70] , had severe anemia [HR: 4.88, 95% CI:4.34,5.49], and had tuberculosis disease

158

[HR: 1.75, 95% CI:1.64,1.87] had a higher hazard rate of all-cause mortality (Table 2).

159

Association between HBV and/or HCV coinfection and all-cause mortality

160
161

The cumulative survival among those with HBV and HCV coinfection was lower
compared to those with HIV mono-infection (log-rank p-value < 0.001) (Figure 2).

162

The mortality rate among PLHIV coinfected with HBV was 4.6, with HCV was 5.1 and

163

with HBV and HCV was 7.7 per 100 person-years. The adjusted HR of all-cause mortality among

164

PLHIV with HBV coinfection was 1.25 (95% CI:1.11,1.40), among those with HCV coinfection

165

it was 1.52 (95% CI: 1.35,1.71), and among those with both HBV and HCV coinfection was 2.14

166

(95% CI: 1.51, 3.02) compared to HIV mono-infection group (Table 3).

167

When stratified by hyperglycemia status, the association between HCV coinfection and

168

mortality was greater among patients with hyperglycemia. Among patients with euglycemia, the

169

adjusted HR for patients with HCV coinfection was 1.44 [95% CI: 1.24, 1.66] and for those with

170

both HBV and HCV coinfection was 1.78 [(5 % CI: 1.14, 2.77] compared to HIV mono-infection

171

group. Among patients with hyperglycemia, the adjusted HR for patients with HCV infection was

172

1.85 [95% CI: 1.23, 2.78] and for those with both HBV and HCV coinfection was 4.39 [95% CI:

173

1.51, 12.76] (Table 3).
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174

Sensitivity analyses

175

To assess the potential misclassification of HBV and/or HCV coinfection, we calculated

176

relative risks (RR) of mortality associated with HBV and/or HCV coinfection using sensitivity and

177

specificity of measurement range from .80 to .99. Compared to HIV mono-infection, the observed

178

RR among HBV coinfection was 1.27, among HCV coinfection was 1.43 and HBV and HCV

179

coinfection was 2.17. From the sensitivity analysis, the point estimate of RRs range from 0.31 to

180

1.38 among HBV coinfection, 0.28 to 1.60 among HCV coinfection and 0.18 to 2.63 among HBV

181

and HCV coinfection. When patients who were lost to follow-up from the program were

182

reclassified as having died and included in the all-cause mortality group, the association between

183

hepatitis coinfection and all-cause mortality remained significant, with a similar effect size [aHR:

184

1.19, 95% CI: 1.09, 1.32 for HBV coinfection, aHR: 1.46, 95% CI: 1.32, 1.60 for HCV coinfection

185

and aHR: 2.36, 95% CI: 1.82, 3.06 for HBV and HCV coinfection]. The e-value for the association

186

between risk of mortality with HBV coinfection and was 1.61, with HCV coinfection was 2.01

187

and with both HBV and HCV coinfection was 2.77 showing that only if there is a strong association

188

between unmeasured confounder with both exposure and outcome could shift our observed

189

association toward null.

190

191

DISCUSSION

192

This study addressed the association between HBV and/or HCV coinfection with all-cause

193

mortality stratified by hyperglycemia status in a large cohort of PLHIV on ART. We found that

194

the prevalence of HBV or HCV coinfection was high in this PLHIV cohort: approximately 9%

195

were HBV or HCV serology positive at enrollment to HIV care. Our study also demonstrated that
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196

coinfection with HBV and/or HCV increased the risk of mortality. The mortality in PLHIV with

197

HBV coinfection was 20% higher at any given point in time compared to PLHIV without hepatitis

198

coinfection. The mortality among PLHIV with HCV coinfection was 50% higher and among

199

PLHIV compared to those without hepatitis coinfection. Among PLHIV with both HBV and HCV

200

coinfection, the hazard of mortality was two-fold higher compared to those without hepatitis

201

coinfection. Importantly, we found that the relationship between HBV and/or HCV coinfection

202

and mortality varied by patient’s hyperglycemia status. The risk of mortality among HCV

203

coinfected or both HBV and HCV coinfected PLHIV was greater in hyperglycemic group.

204

However, the risk of mortality among HBV coinfected PLHIV was greater in euglycemic group.

205

The prevalence of HBV in this cohort is similar to the prevalence found in a previous study

206

conducted in 2012 in the same IHC program [202]. However, the prevalence of HCV coinfection

207

was higher in this study compared to the previous study (9% vs 5%). This may be due to the

208

enrollment of patients who were at higher risk of HCV coinfection, such as patients who were

209

using injection drugs, engaging in sex work, and men who had sex with men to the program after

210

2012. The prevalence of HCV coinfection found in our study was in a higher range compared to

211

that has been reported in a global meta-analysis (2.4%; IQR: 0.8 to 8.4) [38] and was similar to

212

the prevalence of HCV (9.5%) among a male PLHIV cohort enrolled between 2004 and 2014 from

213

a private HIV care clinic in Myanmar supported by Médecins Sans Frontiers [203].

214

PLHIV with HBV and/or HCV had a higher risk of mortality in this cohort. Our findings

215

are commensurate with data from other countries and settings where treatment for HBV or HCV

216

coinfection is not available [40,43,44,204–207]. Most importantly, patients coinfected with both

217

HBV/HCV had the highest risk of mortality, with a two-fold increase in the overall mortality rate
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218

compared to PLHIV without hepatitis virus coinfection. This is similar to other studies which

219

showed that dual HBV/HCV coinfection substantially increased the mortality in PLHIV [42,207].

220

There are growing evidence that HCV coinfection and T2DM together increase the risk of

221

mortality in PLHIV. As many studies suggested, patients with HIV/HCV co-infection are at

222

increased risk of metabolic syndrome including T2DM and predispose to poor clinical outcomes

223

[124,208,209]. A cohort study from Italy reported that among HCV coinfected PLHIV, T2DM

224

was associated with 3-fold risk of liver-related deaths compared to those without T2DM [123].

225

There are also growing evidence suggestion that treatment of HCV can improve the metabolic

226

complications [210]. However, HCV treatment was not available in Myanmar during the study

227

period which could contributed to increased mortality among HCV coinfected PLHIV with

228

hyperglycemia. HCV treatment in PLHIV started available in some cities in 2017 and future

229

studies should be planned to assess the association of HCV treatment with mortality in PLHIV

230

with hyperglycemia or diabetes mellitus.

231

One of the strengths of this study is the use of a large PLHIV cohort that covers one third

232

of PLHIV receiving care in Myanmar in the public health sector, and our results are therefore

233

generalizable to PLHIV in Myanmar. In addition, we had information on date of exposure and

234

outcomes, which allowed us to perform time to event analysis to provide robust estimates of the

235

effect of exposure on mortality.

236

There are some limitations in this study. First, we defined exposure (HBV and/or HCV

237

coinfection status) based on HBs antigen and HCV antibody serology tested at enrollment to the

238

HIV clinic which only provided the acute infection status. About 90% of acute HBV and 50% of

239

acute HCV infection can naturally resolve. Investigations for chronic HBV or HCV status were
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240

not available in this setting. Hence, we could not differentiate between acute, chronic or resolved

241

coinfection. In addition, our data did not capture those who acquired coinfection during follow-

242

up. Further, there could be few patients who received treatment from HCV in private clinic and

243

we did not have information of them. Hence, we cannot make conclusion on whether mortality

244

risk we found is associated with acute or chronic infection.

245

Second, we defined hyperglycemia based on RBG level which has limited validity to assess

246

patient’s glycemic status. This may introduce bias due to misclassification of covariates and may

247

shift our estimates toward or away from null. It is also possible that the misclassification of

248

hyperglycemia status can be differential with respect to mortality. Patients who were very sick

249

may not have enough food and the RBG measurement would capture the low level of glycemia or

250

patients who were very sick may have stress response and the RBG measurement would capture

251

the high level of glycemia. We also cannot identify whether those with hyperglycemia were

252

diagnosed diabetes mellitus or not due to lack of screening and recording.

253

Third, 11% of PLHIV were not tested for hepatitis and thus were excluded from the study.

254

The characteristics of patients who were excluded and included in the analysis were different.

255

Assuming missingness is missing at random, missingness is not monotone and, sex, alcohol

256

consumption, CD4, BMI and anemia as auxiliary variables, we performed multiple imputation

257

using chained equations and estimated the hazard ratios. The HRs for all the models provide similar

258

results. However, if the missingness is not at random, selection bias can still be present.

259

Despite the limitations, there are some public health and clinical implications from this

260

study. First, the prevalence of HBV and HCV coinfection in PLHIV was high in this setting.

261

Accordingly, public health interventions to reduce new hepatitis infections such as HBV
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262

vaccination and harm reduction program should be strengthened for PLHIV to reduce mortality

263

among PLHIV. Reducing coinfection is critical as evidence suggests that even after HBV

264

treatment was available and used as part of the ART regimen, PLHIV with HBV coinfection

265

experienced an increased risk of death compared to those without HBV coinfection [211]. HBV

266

vaccination among those who did not have HBV infection is a recommended strategy in addition

267

to health education and harm reduction among those who have a high risk of HBV infection

268

[39,196].

269

Second, harm reduction prevention programs to reduce HCV infection, especially in high-

270

risk groups, should be strengthen. Third, as HCV coinfection significantly increased mortality

271

among PLHIV, HCV treatment for coinfected patients should be scaled up for the whole country.

272

The newer direct-acting antiviral agents for HCV virus have demonstrated promising results for

273

HIV/HCV coinfected patients and have been shown to decrease mortality among PLHIV

274

[212,213]. In addition, the association between HCV and mortality was higher in PLHIV with

275

hyperglycemia. Hence, clinical guidelines should be developed for screening and management of

276

hyperglycemia and diabetes mellitus for PLHIV with HCV coinfection in this setting. Finally,

277

testing and recording of chronic HBV and HCV status among PLHIV and monitoring the effect of

278

HBV and HCV treatment on HIV clinical outcomes would add to the evidence base towards

279

improving the clinical management of HBV and HCV among PLHIV.

280
281

CONCLUSIONS

282

This study demonstrated a high prevalence of HBV and HCV coinfection among PLHIV

283

and a higher mortality among those coinfected by either HBV or HCV and hyperglycemia. In
86

284

addition to HBV and HCV screening at enrollment to HIV care, chronic HBV and HCV status

285

should be assessed by regularly testing HBV and HCV during follow-up along with HBV panel

286

and HCV RNA testing among those HBV and/or HCV screening positive to better understand the

287

impact of HBV and HCV coinfection on patients’ outcomes. Finally, the treatment for HCV

288

coinfected patients should be scaled up to reduce mortality.
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Figure 1. Flow diagram of the people living with HIV initiated on ART under Integrated
HIV Care Program in Myanmar 2005-2016 stratified by their baseline HBV and/or HCV
coinfection and hyperglycemia status
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Eligible for study
27,722

HIV mono-infection
23,019 (93%)

HBV positive
2,260 (8%)

HCV positive
2,265 (8%)

Both HBV and HCV positive
178(0.6%)

Hyperglycemia
1,123 (5%)

Hyperglycemia
119 (5%)

Hyperglycemia
170 (8%)

Hyperglycemia
13 (7%)

299
300
301

ART: antiretroviral therapy; HBs: hepatitis B surface; HCV: hepatitis C virus; Hyperglycemia:
random blood glucose ≥140 mg/dl

89

Figure 2. Kaplan-Meier survival curve stratified by hepatitis B and/or C coinfection status
among people living with HIV initiated on ART between 2005 and 2017 in Integrated HIV
Care program in Myanmar

Log-rank p- value <0.001

HBV: hepatitis B virus; HCV: hepatitis C virus
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Table 1. Demographic, clinical and treatment characteristics at enrollment of people living with HIV who initiated on
antiretroviral therapy under the Integrated HIV Care Program, Myanmar, 2005-2016 by HBV and/or HCV coinfection status
(N=27,722)

Total
Characteristics
Age in years
Median (IQR)
15-24
25-45
>45
Gender
Male
Female
Random blood glucose level mg/dl
Median (IQR)
Euglycemia (<140)
Hyperglycemia (≥140)
Not recorded
Alcohol drinking
Never
Habitual (daily)
Social (occasionally)
Not recorded
BMI (kg/m2)

n (%)≠
35
1,838
21,887
3,997

(30, 42)
(7)
(79)
(14)

15,764 (57)
11,958 (43)

HIV monoinfection
n=23,019
n (%)©
35
1,537
18,207
3,275

(30, 41)
(84)
(83)
(82)

12,385 (79)
10,634 (89)

HBV
n=2,260

HCV
n=2,265

n (%)©

n (%)©

35
135
1,851
274

(30, 41)
(7)
(9)
(7)

35
156
1,686
423

(30, 43)
(9)
(8)
(11)

35
10
143
25

(30, 40)
(1)
(1)
(1)

1,699 (11)
566 (5)

142 (1)
36 (<1)
95
134
13
31

88 (75, 106)
(76,106)
16,959 (83)
(74)
1,123 (79)
(5)
4,937 (84)
(21)

90
1,676
119
465

(76, 107)
(8)
(8)
(8)

94
1,659
170
436

(77, 114)
(8)
(12)
(7)

18,386
2,370
6,145
821

(66)
(9)
(22)
(3)

15,863
1,834
4,627
695

1,299
278
623
60

(7)
(12)
(10)
(7)

1,140
242
821
62

(6)
(10)
(13)
(8)
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n (%)©

1,538 (10)
722 (6)

90
20,428
1,425
5,869

(86)
(77)
(75)
(85)

HBV and HCV
n=178

84
16
74
4

(79, 118)
(1)
(1)
(1)
(1)
(1)
(1)
(1)

19 (17,22)
19 (17,21)
19 (18,22)
21 (18, 22)
Median (IQR)
19 (17,22)
8,342 (84)
858 (9)
725 (7)
45 (1)
<18.5
9,970 (36)
7,920 (80)
829 (8)
1,018 (10)
86 (1)
18.5-22.9
9,853 (36)
2,821 (84)
245 (7)
273 (8)
26 (1)
23.0-27.5
3,363 (12)
1,421 (89)
113 (7)
63 (4)
2 (<1)
>27.5
1,599 (6)
2,515 (86)
215 (7)
186 (6)
19 (1)
Not recorded
2,933 (11)
WHO clinical staging
9,342 (84)
820 (7)
954 (9)
76 (1)
1 or 2
11,192 (40)
13,667 (83)
1,440 (9)
1,310 (8)
102 (1)
3 or 4
16,519 (60)
10 (91)
0 (0)
1 (9)
0 (0)
Not recorded
11 (<1)
3
CD4 count (cell/mm )
154 (70, 284)
149 (70, 274)
201 (104, 329) 209 (116,337)
Median (IQR)
158 (72,287)
3,816 (82)
335 (7)
476 (10)
41 (1)
>350
4,668 (17)
5,289 (81)
523 (8)
657 (10)
53 (1)
200-349
6,522 (24)
13,741 (84)
1,380 (9)
1,120 (7)
81 (1)
<200
16,323 (59)
173 (82)
22 (11)
12 (6)
3 (1)
Not recorded
210 (1)
Anemia
6,879 (80)
686 (8)
925 (11)
76 (1)
No anemia
8,566 (31)
13,964 (84)
1,375 (8)
1,184 (7)
87 (1)
Mild to Moderate
16,610 (60)
1,798 (86)
155 (7)
123 (6)
12 (1)
Severe
2,088 (8)
378 (83)
44 (10)
33 (7)
3 (1)
Not recorded
458 (2)
Tuberculosis disease
16,171 (83)
1,516 (8)
1,634 (8)
131 (1)
No
19,452 (70)
6,848 (83)
744 (9)
631 (8)
47 (1)
Yes
8,270 (30)
Initiated on TDF and lamivudine
12,344 (88)
725 (5)
992 (7)
39 (<1)
No
14,100 (51)
10,675 (78)
1,535 (11)
1,273 (9)
139 (1)
Yes
13,622 (49)
Col: column, IQR: interquartile range, BMI: body mass index, TDF: tenofovir disoproxil fumarate
≠
Column percentage, ©Row percentage of total
¥
Patients who received TB treatment at enrollment to HIV care or started TB treatment within 90 days of enrollment to HIV care
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Table 2. Demographic, clinical and treatment characteristics at enrollment associated with all-cause mortality among people
living with HIV who initiated on antiretroviral therapy under the Integrated HIV Care Program, Myanmar, 2005-2016
(N=27,722)

Characteristics
Total
Age in years
<25
25-45
>45

All-cause mortality
Rate [95% CI]
HR [95% CI]

Person-years

n

96,994
5813
78545
12637

3655
161
2813
681

3.8 [3.7, 3.9]
2.8 [2.4, 3.2]
3.6 [3.5, 3.7]
5.4 [5, 5.8]

Ref
1.4 [1.19,1.64]
1.98 [1.67,2.35]

54248
42747

2562
1093

4.7 [4.5, 4.9]
2.6 [2.4, 2.7]

1.83 [1.71,1.97]
Ref

66841
4464
25690

2681
241
733

4 [3.9, 4.2]
5.4 [4.8, 6.1]
2.9 [2.7, 3.1]

Ref
1.33 [1.17, 1.52]
0.84 [0.77, 0.91]

66242
7635
19185
3932

2179
491
897
88

3.3 [3.2, 3.4]
6.4 [5.9, 7]
4.7 [4.4, 5]
2.2 [1.8, 2.8]

Ref
1.87 [1.69,2.06]
1.32 [1.22,1.42]
0.80 [0.64,0.99]

37524
36489
11700
4453
6829

1748
959
208
100
640

4.7 [4.4, 4.9]
2.6 [2.5, 2.8]
1.8 [1.6, 2]
2.2 [1.8, 2.7]
9.4 [8.7, 10.1]

1.82 [1.68,1.97]
Ref
0.65 [0.56,0.75]
0.71 [0.58,0.88]
2.84 [2.57,3.14]

36927

704

1.9 [1.8, 2.1]

Gender
Male
Female
Random blood glucose level
Euglycemia (<140)
Hyperglycemia (≥140)
Not recorded
Alcohol drinking
Never
Habitual (daily)
Social (occasionally)
Not recorded
BMI category
<18.5
18.5-22.9
23-27.5
>27.5
Not recorded
Baseline WHO staging
1 or 2
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Ref

3 or 4
60022
2949
4.9 [4.7, 5.1]
2.83 [2.60, 3.07]
Not recorded
46
2
4.4 [1.1, 17.5]
2.95 [0.74, 11.81]
Baseline CD4 count (cell/mm3)
>350
14804
239
1.6 [1.4, 1.8]
Ref
200-349
23035
499
2.2 [2, 2.4]
1.43 [1.23,1.67]
<200
59000
2774
4.7 [4.5, 4.9]
3.24 [2.84,3.70]
Not recorded
156
143
91.4 [77.6, 107.7]
34.54 [28.05,42.54]
Anemia
No anemia
29207
533
1.8 [1.7, 2]
Ref
Mild to Moderate
59845
2486
4.2 [4, 4.3]
2.41 [2.19,2.64]
Severe
6407
566
8.8 [8.1, 9.6]
4.88 [4.34,5.49]
Not recorded
1535
70
4.6 [3.6, 5.8]
2.64 [2.05,3.38]
¥
Tuberculosis disease
No
65575
2070
3.2 [3, 3.3]
Ref
Yes
31420
1585
5 [4.8, 5.3]
1.75 [1.64,1.87]
Initiated on TDF and lamivudine
No
66265
2105
3.2 [3, 3.3]
Ref
Yes
30730
1550
5 [4.8, 5.3]
1.02 [0.95,1.09]
Ref: reference group, BMI: body mass index, TDF: tenofovir disoproxil fumarate
¥
Patients who received TB treatment at enrollment to HIV care or started TB treatment within 90 days of enrollment to HIV care.
Bold indicates 95% confidence interval estimate did not include null value.
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Table 3. Association between HBV and/or HCV coinfection and all-cause mortality among people living with HIV who initiated
on antiretroviral therapy under the Integrated HIV Care Program, Myanmar, 2005-2016
All-cause mortality
Number

Personyears

n

Rate¥

Total

27,722

96,994

3655

3.8

[3.7,

3.9]

HIV mono-infection

23,019

82,184

2932

3.6

[3.4,

3.7]

Ref

HBV

2,260

7,885

358

4.6

[4.1,

5.1]

1.37

[1.23, 1.54]

1.25

[1.11,

1.40]

HCV

2,265

6,498

332

5.1

[4.6,

5.7]

1.50

[1.33, 1.69]

1.52

[1.35,

1.71]

HBV and HCV

178

428

33

7.7

[5.5, 10.9]

2.27

[1.61, 3.21]

2.14

[1.51,

3.02]

[95% CI]

HR€

[95% CI]

aHR€*

[95% CI]

All patients

Ref

Patients with euglycemia (RBG <140mg/dl)
Total

20,428

66841

2681

4.0

[3.9,

4.2]

HIV mono-infection

16,959

56557

2160

3.8

[3.7,

4.0]

Ref

HBV

1,676

5444

274

5.0

[4.5,

5.7]

1.43

[1.26

1.62]

1.28

[1.12,

1.46]

HCV

1,659

4512

227

5.0

[4.4,

5.7]

1.39

[1.21, 1.61]

1.44

[1.24,

1.66]

HBV and HCV

134

328

20

6.1

[3.9,

9.5]

1.72

[1.11, 2.69]

1.78

[1.14,

2.77]
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Ref

Patient with hyperglycemia (RBG ≥140 mg/dl)
Total

1,425

4464

241

5.4

[4.8,

6.1]

HIV mono-infection

1,123

3,706

181

4.9

[4.2,

5.7]

Ref

HBV

119

387

21

5.3

[3.5,

8.3]

1.16

[0.73, 1.83]

0.95

[0.59,

1.51]

HCV

170

356

35

9.8

[7.1, 13.7]

1.79

[1.19, 2.67]

1.85

[1.23,

2.78]

HBV and HCV

13

16

4

25.6

[9.6 68.3]

4.22

[1.50, 11.93]

4.39

[1.51, 12.76]

Ref

HR: hazard ratio; aHR: adjusted HR; HBV: hepatitis B virus; HCV: hepatitis C virus, Ref: reference group
¥ Rate
€

per 100 person-years follow-up

proportional hazard assumption did not hold for the exposure variable and included as a time varying covariate in the model

*adjusted for age, gender, alcohol drinking history, body mass index, CD4+ T cell count, anemia, and tuberculosis disease at enrollment,
initiated on TDF plus lamivudine regimen or not, and year of ART initiation
Likelihood ratio p-value for statistical interaction term between HBV and/or HCV coinfection and hyperglycemia status = 0.09
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Chapter 5: Summary and Future Directions in Research
5.1 Overview of findings
Overall, the findings from the three studies suggests that comorbidities with chronic
infectious diseases – TB, HBV and HCV and non-infectious comorbidity – hyperglycemia in
PLHIV is associated with poor clinical outcomes.
The results of the study 1 suggested that there is a biological interaction between low BMI
and hyperglycemia on the risk of TB disease among PLHIV. Study 1 included 20,865 PLHIV
enrolled in 49 HIV clinics in Myanmar between 2011 and 2017. In this cohort, the median age was
36 years (range 15-91 years), 11,538 (55%) were male, 7,610 (36%) had low BMI, 1,324 (6%) had
hyperglycemia. During the median follow-up of 2.2 (IQR: 0.5-4.2), 3,628 (17%) developed active
TB and the incidence rate of active TB was seven cases per 100 person-years. From the adjusted
Cox proportional hazards model, we observed that the hazard rate of incident TB among PLHIV
with joint exposure was 1.84 times compared to those with no exposure (95% CI: 1.55, 2.18).
There was a biological interaction between two exposure (synergy index: 2.01, 95% CI: 1.09,
3.74), the relative excess risk (of TB disease) due to the interaction of two exposures was 0.42
(95% CI:0.07, 0.78) and the attributable proportion to the risk of TB due to joint exposure was
23%.
The results of the study 2 showed that one in five PLHIV in the study cohort had prevalent
of TB and 21% of the PLHIV in the cohort died during one year of follow-up. PLHIV with active
TB experienced higher mortality and lower CD4 cell counts compared to PLHIV without TB.
PLHIV with active TB experienced similar CD4 cell count increase as in their counterpart once
they were initiated on ART. This study included 1,871 adult PLHIV enrolled in one outpatient
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HIV clinic in Myanmar between 2011 and 2018. In this cohort, 687 (37%) had CD4 cell count
<100 cell/mm3 and 394 (21%) had active TB within 90 days of enrollment to HIV care. The
median random blood glucose level was 86 mg/dl (interquartile range: 74, 99). One-year all-cause
mortality was significantly associated active TB [adjusted relative risk:1.75, 95% CI:1.38, 2.21].
The mean log CD4 cell count during the follow-up was significantly lower in PLHIV with active
TB compared to those without active TB [βTB = -0.61, 95% CI: -0.71, -0.51, βTB*follow-up
month= 0.04, 95% CI: 0.03, 0.05]. However, we did not observe clinically meaningful role of
glycemic level as a mediator in the relationship between active TB and all-cause mortality
The results of the study 3 suggests that PLHIV coinfected with HBV or HCV experienced
higher rates of mortality and the mortality was greater among those comorbid with hyperglycemia.
This study used cohort data of 27,722 adult PLHIV enrolled in 49 HIV clinics in Myanmar between
2005 and 2016. Among them, 2,260 (8%) had HBV, 2,265 (9%) had HCV, 178 (0.6%) had both
HBV/HCV coinfection and 1425 (5%) had hyperglycemia. During the median follow-up of 3.1
years (IQR 1.5 – 5.1), 3655 (13%) patients died and the overall mortality rate was 3.8 (95%
CI:3.7,3.9) per 100 person-years. There was a significant association between hepatitis virus
coinfections and all-cause mortality [adjusted HR: 1.25 (95% CI:1.11,1.40) for HBV, 1.52 (95%
CI: 1.35,1.71) for HCV and 2.14 (95% CI: 1.51, 3.02) for HBV/HCV coinfection]. The association
was stronger in patients with hyperglycemia [adjusted hazard ratios: 1.58 (95% CI: 1.09, 2.30) for
HCV and 3.21 (95% CI: 1.17, 8.84) for HBV/HCV coinfection compared to HIV mono-infection].
5.2 Public health and clinical implications
The findings of this dissertation project have many public health and clinical implications.
From study 1, we identified the PLHIV subgroup which has the highest risk of TB disease.
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Identification of subgroups with a high risk of TB disease is important to effectively allocate the
public health resources to target the intervention to reduce TB incidence. As Myanmar is a
resource-limited country, intervention to prevent TB disease such as providing isoniazid therapy
should be prioritized for the group with the highest risk. In addition, interventions such as
providing a nutritional supplementation to improve weight gain and diagnosis and treatment of
hyperglycemia and T2DM to reduce the risk of TB disease in PLHIV especially among joint
exposure group should be considered. In addition, we observed that habitual alcohol consumption
was associated with underweight and risk of TB disease. Hence, HIV program should consider
investing resources for patient counselling to reduce alcohol use to prevent adverse clinical
outcomes.
Findings from study 2 highlighted a high prevalence of TB in PLHIV, the adverse clinical
outcomes in PLHIV with TB comorbidity and deficiency of T2DM screening and viral load testing
or recording in HIV program. As patients with active TB disease had a higher mortality, TB
preventive interventions should be urgently implemented in this setting. In addition, PLHIV with
active TB in our study showed decent CD4 count increase once they were on both ART and TB
treatment. Hence, PLHIV should be screened for early diagnosis and treatment active TB as well
as initiated on ART early to prevent mortality related to severe immunodeficiency. In this setting,
fasting blood glucose or HbA1c is not routinely used to screen T2DM. High RBG level was
associated with mortality in this study, the HIV management clinical guideline should include
screening of T2DM and management of hyperglycemia in Myanmar. However, the role of
glycemia in TB/HIV related mortality and the optimal timing and level of blood glucose level in
TB and HIV coinfection are unknown, caution should be made in control of hyperglycemia. The
viral load testing is low in this study site and needs to be increased to assess the actual prevalence
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of virological failure. One of the reasons is because the study site does not have viral load testing
facilities and the closet viral load testing facility is about 200 miles away and required blood
sample transportation. HIV program needs to develop strategy to improve access to T2DM
screening and viral load testing in PLHIV.
Study 3 demonstrated a high prevalence of HBV and HCV coinfection among PLHIV and
a higher mortality among those coinfected by either HBV or HCV and hyperglycemia in Myanmar.
Accordingly, national public health programs should implement or strengthen public health
interventions to reduce new hepatitis infections to reduce mortality among PLHIV. Prevention
coinfection is critical as even after HBV treatment, PLHIV with HBV coinfection experienced an
increased risk of death compared to those without HBV coinfection. HBV vaccination should be
scaled up among PLHIV. In addition, harm reduction prevention programs to reduce HCV
infection, especially in high-risk groups, should be strengthen. For those HCV coinfected PLHIV,
strategy should be explored to scale up the HCV treatment using the newer direct-acting antivirals
for the whole country. The newer direct-acting antivirals have demonstrated promising results for
HIV/HCV coinfected patients and have been shown to decrease mortality among PLHIV. In
addition, the association between HCV and mortality was stronger in PLHIV with hyperglycemia.
Hence, screening, recording and management of hyperglycemia and diabetes mellitus should be
considered in this setting. Finally, testing and recording of chronic HBV and HCV status among
PLHIV and monitoring the effect of HBV and HCV treatment on HIV clinical outcomes should
be implemented and strengthen in HIV program.
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5.3 Future directions in research
One of the major limitations of this project is using random blood glucose measurement to
define hyperglycemia which has limited validity than fasting blood glucose or HbA1c
measurement. In addition, there is no information on diabetes diagnosis and treatment after the
random blood glucose measurement and during the follow-up. Hence, in future study, we need to
measure fasting blood glucose or HbA1c to define hyperglycemia and collect information on
diabetes medications. In addition, there are unmeasured confounders which we addressed using
sensitivity analyses. In future study, we will collect data on cigarette smoking history which is a
known risk factor for diabetes mellitus and TB disease and diabetes melilites treatment which can
be associated with glycemic level and TB disease.
In this study, we only adjusted for potential confounders using the baseline patient
characteristics in the final model and some covariates may have time varying effect on outcome.
As this dataset has data of each visit, this could be used to analyze the time varying effect of the
cofounders.
Our study cannot assess the direction of relationship between hyperglycemia and TB. Thus,
future epidemiologic studies are needed to assess the direction of relationship between T2DM and
TB in PLHIV using prospective longitudinal study design. In addition, longitudinal studies that
assess the association between hyperglycemia with clinical outcomes such as immune restoration
and mortality in HIV/TB patients are critically important to inform the clinical management.
Furthermore, screening of T2DM and hyperglycemia is not integrated into most HIV care practice.
Additional data is urgently needed to inform screening and clinical management of T2DM and TB
comorbidity in PLHIV. Further studies that generate evidence to inform optimal timing and
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methods for screening and diagnosis T2DM and management of hyperglycemia in HIV/TB
patients are also needed.
In this setting, HBV and HCV infection were assessed one time at enrollment. We could
not differentiate between acute, chronic or resolved coinfection and we also could not detect those
who acquired coinfection during follow-up. We need to measure HBV and HCV serology panels
in PLHIV longitudinally to determine the chronic infection to estimate the impact of chronic
infection on T2DM and mortality.
5.4 Conclusions
Findings from this dissertation will inform clinical care of PLHIV in low- and middleincome countries. Our results suggest that 1) PLHIV with hyperglycemia and low BMI represent
a subgroup with high risk of TB incidence, 2) PLHIV with active TB experience higher mortality
and lower mean CD4 cell counts during the follow-up, and 3) hepatitis coinfection and
hyperglycemia are associated with higher risk of mortality in PLHIV.. This dissertation also
highlighted the critical need for further studies to understand the synergism between infectious and
non-infectious disease comorbidities in PLHIV and the need for guidelines to prevent and manage
TB, HBV, HCV and hyperglycemia in PLHIV.
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Abbreviations
ART

antiretroviral therapy

CI

confidence interval

FBG

fasting blood glucose

HBV

hepatitis B virus

HbA1c

glycated hemoglobin A1c

HCV

hepatitis C virus

HIV

human immunodeficiency virus

MTB

Mycobacterium tuberculosis

PLHIV

people living with HIV

RBG

random blood glucose

T2DM

type 2 diabetes mellitus

TB

tuberculosis

WHO

World Health Organization
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